Covid Vaccine Scientific Proof

Covid Vaccine Scientific Proof Lethal
• Post published:5 January 2022
COVID-19 Vaccines: Scientific Proof of Lethality
Post published: 5 January 2022 at https://www.saveusnow.org.uk/covid-vaccine-scientific-proof-lethal
Over One Thousand Scientific Studies Prove That the COVID-19 Vaccines Are Dangerous, and All Those
Pushing This Agenda Are Committing the Indictable Crime of Gross Misconduct in Public Office
Just over 12 months from deployment of the COVID 19 emergency use experimental vaccines, scientific
studies in the thousands, and reports of criminal complaints of assault and murder from the illegal,
unlawful use of biochemical poisons made to police forces around the country, verify an assault on an
unsuspecting UK population. Irrefutable science shows that the COVID 19 vaccine is not safe and not
effective in limiting transmission or infection from the SARS-CoV-2, coronavirus pathogens.
The “safe and effective” false propaganda, put out by public officials who now are continuing to push
this vaccine, is a clear breach of duty. A public office holder is subject to, and aware of, a duty to prevent
death or serious injury that arises only by virtue of the functions of the public office.
Many have breached that duty and, in doing so, are recklessly causing a risk of death or serious injury,
by carrying on regardless of the now-confirmed dangers associated with COVID 19 injections. Some of
these risks are blood clotting, myocarditis, pericarditis, thrombosis, thrombocytopenia, anaphylaxis,
Bell’s palsy, Guillain-Barre, cancer including deaths, etc.
All of these are confirmed in the following science-and-government-gathered data from the UK Health
and Security agency on COVID 19 regarding vaccine damage.
The term “vaccine” was changed recently to incorporate this illegal, unlawful medical experiment to
facilitate usage of mRNA technology that is demonstrably not a vaccine, and which contains biologically
toxic nano-metamaterials associated with 5G urban data gathering capability.
Metal nanoparticulates are known in science to be genotoxic—a poison that can also cause sterilization.
The dangers posed to the victims in the near term from this medical battery are now known. However,
the long term lethality of this weapon is not as yet realized due to the debilitating effects it has on the
immune system, causing Acquired Immunodeficiency Syndrome(AIDS).
We can now confirm the 2017 depopulation defence-intelligence documents, showing the planned
murder of over 55 million across the United Kingdom by 2025 using this biochemical weapon.
The Medicines and Healthcare (products) Regulatory Agency (MHRA) had prior warning of the expected
large numbers of adverse reactions before the deployment—confirming the premeditated nature of the
crime and public conduct offences then and now.
1. Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort
study: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/
2. Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular

coagulation and death after ChAdOx1 nCoV-19
vaccination: https://www.sciencedirect.com/science/article/pii/S1052305721003414
3. Fatal cerebral hemorrhage after COVID-19

vaccine: https://pubmed.ncbi.nlm.nih.gov/33928772/
4. Myocarditis after mRNA vaccination against SARS-CoV-2, a case

series: https://www.sciencedirect.com/science/article/pii/S2666602221000409
5. Three cases of acute venous thromboembolism in women after vaccination against COVID-
19: https://www.sciencedirect.com/science/article/pii/S2213333X21003929
6. Acute thrombosis of the coronary tree after vaccination against COVID-

19: https://www.sciencedirect.com/science/article/abs/pii/S1936879821003988
7. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination
with Ad26.COV2.S (against covid-19), March 2 to April 21,
2020: https://pubmed.ncbi.nlm.nih.gov/33929487/
8. Portal vein thrombosis associated with ChAdOx1 nCov-19

vaccine: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/
9. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in

subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian
Society for the Study of Hemostasis and Thrombosis
(SISET): https://pubmed.ncbi.nlm.nih.gov/33871350/
10. Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus
thrombosis after vaccination with COVID-19; a systematic
review: https://www.sciencedirect.com/science/article/pii/S0022510X21003014
11. Thrombosis with thrombocytopenia syndrome associated with COVID-19

vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381
12. Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important

and practical clinical
dilemma: https://www.sciencedirect.com/science/article/abs/pii/S0033062021000505
13. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector
14. COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause

of splanchnic vein
thrombosis: https://www.sciencedirect.com/science/article/pii/S1665268121000557
15. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune
thrombotic immune thrombocytopenia
(covid): https://www.sciencedirect.com/science/article/pii/S1050173821000967
16. Roots of autoimmunity of thrombotic events after COVID-19

vaccination: https://www.sciencedirect.com/science/article/abs/pii/S1568997221002160
17. Cerebral venous sinus thrombosis after vaccination: the United Kingdom
experience: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-
8/fulltext
18. Thrombotic immune thrombocytopenia induced by SARS-CoV-2

vaccine: https://www.nejm.org/doi/full/10.1056/nejme2106315
19. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military.
This article reports that in “23 male patients, including 22 previously healthy military members,
myocarditis was identified within 4 days after receipt of the
vaccine”: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601
20. Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-

19: https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRelated_arti
cle
21. Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series
of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
22. Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-

19: https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRelated_arti
cle
23. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-

19): https://haematologica.org/article/view/haematol.2021.279075
24. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA

vaccines reported to the Vaccine Adverse Event Reporting System
(VAERS): https://www.sciencedirect.com/science/article/pii/S0264410X21005247
25. Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19

vaccination: https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-
052478
26. Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI
revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old
man. https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005
27. Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and

Ad26.COV.2.S
28. Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after
SARS-CoV-2
vaccination: https://www.sciencedirect.com/science/article/abs/pii/S0049384821003315
29. Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis
of European data: https://www.sciencedirect.com/science/article/pii/S0896841121000937
30. Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2

vaccine: https://www.sciencedirect.com/science/article/abs/pii/S1052305721003098
31. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by
the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine
(VITT): https://www.sciencedirect.com/science/article/pii/S0953620521002363
32. Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for
care providers: https://www.sciencedirect.com/science/article/pii/S0828282X21006243
33. “Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient
with antiphospholipid
syndrome”: https://www.sciencedirect.com/science/article/pii/S2666572721000389
34. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous
sinus thrombosis after vaccination with
Ad26.COV2.S: https://www.sciencedirect.com/science/article/pii/S0196064421003425
35. Myocarditis, pericarditis and cardiomyopathy after COVID-19

36. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT)

compared to natural SARS-CoV-2
infection: https://www.sciencedirect.com/science/article/abs/pii/S0896841121000706
37. Prothrombotic immune thrombocytopenia after COVID-19

38. Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success

story: https://www.sciencedirect.com/science/article/pii/S2589936821000256
39. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia
after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with
conventional heparin-warfarin based
anticoagulation: https://www.sciencedirect.com/science/article/pii/S1871402121002046
40. Thrombosis after COVID-19 vaccination: possible link to ACE

pathways: https://www.sciencedirect.com/science/article/pii/S0049384821004369
41. Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with
adenovirus and after COVID-
19: https://www.sciencedirect.com/science/article/pii/S0735109721051949
42. A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca
COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0735675721005714
43. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of
two cases in the United
Kingdom: https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X
44. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-
19): https://www.sciencedirect.com/science/article/abs/pii/S0006497121013963.
45. Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw
that breaks the camel’s
back?: https://docs.google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ
46. Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the
battle against the COVID-19 pandemic: What
pathogenesis?: https://www.sciencedirect.com/science/article/pii/S0953620521002314
47. Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the
management of cerebral venous thrombosis related to COVID-19
48. Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca
COVID-19 vaccine”: https://pubmed.ncbi.nlm.nih.gov/33918932/
49. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2

vaccination: https://pubmed.ncbi.nlm.nih.gov/33606296/
50. Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2

51. Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19

vaccine: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/
52. COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using
data from VigiBase: https://pubmed.ncbi.nlm.nih.gov/33863748/
53. Cerebral venous thrombosis associated with the covid-19 vaccine in

Germany: https://onlinelibrary.wiley.com/doi/10.1002/ana.26172
54. Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-
CoV-2: a black swan event: https://pubmed.ncbi.nlm.nih.gov/34133027/
55. The importance of recognizing cerebral venous thrombosis following anti-COVID-19

56. Thrombosis with thrombocytopenia after messenger RNA vaccine -

57. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of
European data: https://pubmed.ncbi.nlm.nih.gov/34174723/
58. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic,
thromboembolic, and hemorrhagic events in
Scotland: https://www.nature.com/articles/s41591-021-01408-4
59. Exacerbation of immune thrombocytopenia after COVID-19

60. First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19
61. PF4 immunoassays in vaccine-induced thrombotic

thrombocytopenia: https://www.nejm.org/doi/full/10.1056/NEJMc2106383
62. Antibody epitopes in vaccine-induced immune immune thrombotic

thrombocytopenia: https://www.nature.com/articles/s41586-021-03744-4
63. Myocarditis with COVID-19 mRNA

vaccines: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135
64. Myocarditis and pericarditis after COVID-19

vaccination: https://jamanetwork.com/journals/jama/fullarticle/2782900
65. Myocarditis temporally associated with COVID-19

vaccination: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891.
66. COVID-19 Vaccination Associated with Myocarditis in

Adolescents: https://pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/peds.
2021-053427.full.pdf
67. Acute myocarditis after administration of BNT162b2 vaccine against COVID-

68. Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case
report and review of the
literature: https://www.sciencedirect.com/science/article/pii/S1553838921005789
69. COVID-19 vaccine-induced myocarditis: a case report with review of the

70. Potential association between COVID-19 vaccine and myocarditis: clinical and CMR
findings: https://www.sciencedirect.com/science/article/pii/S1936878X2100485X
71. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA
disease vaccine 2019 (COVID-19) in a male
adolescent: https://www.sciencedirect.com/science/article/pii/S002234762100617X
72. Fulminant myocarditis and systemic hyper inflammation temporally associated with BNT162b2
COVID-19 mRNA vaccination in two
patients: https://www.sciencedirect.com/science/article/pii/S0167527321012286.
73. Acute myocarditis after administration of BNT162b2
vaccine: https://www.sciencedirect.com/science/article/pii/S2214250921001530
74. Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral

vector: https://www.sciencedirect.com/science/article/pii/S2352906721001573
75. Myocarditis following vaccination with BNT162b2 in a healthy

male: https://www.sciencedirect.com/science/article/pii/S0735675721005362
76. Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-
CoV-2 infection: https://www.sciencedirect.com/science/article/pii/S1930043321005549
77. Myopericarditis after Pfizer mRNA COVID-19 vaccination in

adolescents: https://www.sciencedirect.com/science/article/pii/S002234762100665X
78. Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA

79. Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273

mRNA: https://www.sciencedirect.com/science/article/pii/S2589790X21001931
80. Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and
cardiac involvement in a patient with previous SARS-COV-2
infection: https://www.sciencedirect.com/science/article/pii/S2352906721000622
81. Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of

age: https://www.sciencedirect.com/science/article/pii/S0022347621007368
82. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old

man: https://www.sciencedirect.com/science/article/pii/S0870255121003243
83. Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in
adolescents: https://www.sciencedirect.com/science/article/pii/S0022347621007496
84. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and
BNT162b2: https://www.sciencedirect.com/science/article/pii/S1936878X21004861
85. Takotsubo cardiomyopathy after vaccination with mRNA COVID-

19: https://www.sciencedirect.com/science/article/pii/S1443950621011331
86. COVID-19 mRNA vaccination and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34268277/
87. COVID-19 vaccine and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34399967/
88. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-
19 mRNA vaccine in Korean children: a multicenter study https://search.bvsalud.org/global-
literature-on-novel-coronavirus-2019-ncov/resourc e/en/covidwho-1360706.
89. COVID-19 vaccines and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34246566/
90. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19

vaccines https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-comp
lications-of-the-mrna-based-covid-19-vaccines https://www.cureus.com/articles/61030-
myocarditis-and-other-cardiovascular-complications-of-the-mrna-based-covid-19-vaccines
91. Myocarditis, pericarditis, and cardiomyopathy after COVID-19

92. Myocarditis with covid-19 mRNA

vaccines: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135
93. Association of myocarditis with COVID-19 mRNA vaccine in

children: https://media.jamanetwork.com/news-item/association-of-myocarditis-with-mrna-co
vid-19-vaccine-in-children/
94. Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of
children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
95. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S.
military: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601%5C
96. Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19

vaccines: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600
97. Myocarditis following immunization with Covid-19

mRNA: https://www.nejm.org/doi/full/10.1056/NEJMc2109975
98. Patients with acute myocarditis after vaccination withCOVID-19

mRNA: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602
99. Myocarditis associated with vaccination with COVID-19

mRNA: https://pubs.rsna.org/doi/10.1148/radiol.2021211430
100. Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19

Vaccination: https://pediatrics.aappublications.org/content/148/3/e2021052478
101. Cardiovascular magnetic resonance imaging findings in young adult patients with acute
myocarditis after COVID-19 mRNA vaccination: a case series: https://jcmr-
online.biomedcentral.com/articles/10.1186/s12968-021-00795-4
102. Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination
with COVID-19 mRNA: https://www.cps.ca/en/documents/position/clinical-guidance-for-youth-
with-myocarditis-and-pericarditis
103. Cardiac imaging of acute myocarditis after vaccination with COVID-19

mRNA: https://pubmed.ncbi.nlm.nih.gov/34402228/
104. Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA
vaccine: https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567
105. Myocarditis / pericarditis associated with COVID-19

vaccine: https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html
106. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19
vaccine: https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolesce
nts_Receiving.95800.aspx
107. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19

vaccine: https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543
108. The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible
underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34312010/
109. Acute myocardial injury after COVID-19 vaccination: a case report and review of current
evidence from the Vaccine Adverse Event Reporting System
database: https://pubmed.ncbi.nlm.nih.gov/34219532/
110. Be alert to the risk of adverse cardiovascular events after COVID-19

vaccination: https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033
111. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac

tomography, and magnetic resonance imaging
findings: https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236
112. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-
19 mRNA vaccine: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038
113. Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an

accidental coincidence or rather a vaccination-associated autoimmune
myocarditis?: https://pubmed.ncbi.nlm.nih.gov/34333695/
114. Recurrence of acute myocarditis temporally associated with receipt of coronavirus

mRNA disease vaccine 2019 (COVID-19) in a male
adolescent: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/
115. Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced

reaction?: https://pubmed.ncbi.nlm.nih.gov/34118375/
116. Self-limited myocarditis presenting with chest pain and ST-segment elevation in
adolescents after vaccination with the BNT162b2 mRNA
117. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination:

Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/
118. Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-
year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/
119. Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis:

could accidental intravenous injection of a vaccine induce
myopericarditis https://academic.oup.com/cid/advance-
article/doi/10.1093/cid/ciab741/6359059
120. Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237
121. Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273
vaccine in a young healthy male: case
report: https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183
122. Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal
relationship: https://pubmed.ncbi.nlm.nih.gov/34236331/
123. Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA

124. COVID-19 vaccine-induced rhabdomyolysis: case report with literature

review: https://pubmed.ncbi.nlm.nih.gov/34186348/.
125. GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report,
systemic review, and implications for vaccine
development: https://www.sciencedirect.com/science/article/pii/S2666354621000065
126. Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual

association: https://www.sciencedirect.com/science/article/pii/S0303846721004169
127. Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases
and review of the
128. Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary
occurrence, not a causal
association: https://www.sciencedirect.com/science/article/pii/S2214250921000998.
129. Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a
case report: https://www.sciencedirect.com/science/article/pii/S0736467921006442
130. Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first
report: https://www.sciencedirect.com/science/article/pii/S0035378721005853.
131. SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following
132. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic

response to methylprednisolone: a case
report: https://www.sciencedirect.com/science/article/pii/S2049080121007536
133. Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-
report database: https://www.sciencedirect.com/science/article/pii/S1201971221007049
134. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine:

cause or coincidence: https://www.sciencedirect.com/science/article/pii/S0899707121003557.
135. New-onset refractory status epilepticus after ChAdOx1 nCoV-19
136. Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal

association: https://www.sciencedirect.com/science/article/pii/S0165572821002137
137. Bell’s palsy and SARS-CoV-2 vaccines: an unfolding

story: https://www.sciencedirect.com/science/article/pii/S1473309921002735
138. Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a
history of recurrent Bell’s
palsy: https://www.sciencedirect.com/science/article/pii/S266635462100020X
139. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA
vaccine:. https://www.sciencedirect.com/science/article/pii/S2451993621001456.
140. Bell’s palsy after COVID-19 vaccination: case

report: https://www.sciencedirect.com/science/article/pii/S217358082100122X.
141. An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using
patient’s allergy
history: https://www.sciencedirect.com/science/article/pii/S2213219821007972
142. COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in

PET: https://www.sciencedirect.com/science/article/pii/S1930043321002612
143. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19

144. Late cutaneous reactions after administration of COVID-19 mRNA

vaccines: https://www.sciencedirect.com/science/article/pii/S2213219821007996
145. COVID-19 vaccine-induced rhabdomyolysis: case report with review of the

146. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-
REPP: a registry-based
study: https://www.sciencedirect.com/science/article/pii/S0190962221024427
147. Thrombosis with thrombocytopenia syndrome associated with COVID-19

vaccines:. https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381.
148. COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee

of the World Allergy
Organization:. https://www.sciencedirect.com/science/article/pii/S1939455121000119.
149. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without
thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid
Indian male treated with conventional heparin-warfarin-based
anticoagulation:. https://www.sciencedirect.com/science/article/pii/S1871402121002046.
19:. https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X
151. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of
European data:. https://www.sciencedirect.com/science/article/pii/S0896841121000937.
152. immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2

mRNA vaccine:. https://www.sciencedirect.com/science/article/pii/S2214250921002018.
153. Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna)
vaccine: Case report: https://www.sciencedirect.com/science/article/pii/S1876034121001878.
154. COVID-19 RNA-based vaccines and the risk of prion disease:

https://scivisionpub.com/pdfs/covid19rna-based-vaccines-and-the-risk-of-prion-dis ease-
1503.pdf
155. This study notes that 115 pregnant women lost their babies, out of 827 who
participated in a study on the safety of covid-19
vaccines: https://www.nejm.org/doi/full/10.1056/NEJMoa2104983.
156. Process-related impurities in the ChAdOx1 nCov-19

vaccine: https://www.researchsquare.com/article/rs-477964/v1
157. COVID-19 mRNA vaccine causing CNS inflammation: a case

series: https://link.springer.com/article/10.1007/s00415-021-10780-7
158. Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-
BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33475702/
159. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene
glycol: https://pubmed.ncbi.nlm.nih.gov/33320974/
160. Pfizer Vaccine Raises Allergy Concerns: https://pubmed.ncbi.nlm.nih.gov/33384356/
161. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech
COVID-19 vaccine – United States, December 14-23,
162. Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19
vaccine – United States, December 21, 2020-January 10,
163. Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea,
February 26-April 30, 2021: https://pubmed.ncbi.nlm.nih.gov/34414880/
164. Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14,
2020-Jan 18, 2021: https://pubmed.ncbi.nlm.nih.gov/33576785/
165. Immunization practices and risk of anaphylaxis: a current, comprehensive update of

COVID-19 vaccination data: https://pubmed.ncbi.nlm.nih.gov/34269740/
166. Relationship between pre-existing allergies and anaphylactic reactions following
administration of COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34215453/
167. Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy

Research: https://pubmed.ncbi.nlm.nih.gov/33932618/
168. Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine
in Great Britain and the USA: Position Statement of the German Allergy Societies: German
Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical
Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine
(GPA): https://pubmed.ncbi.nlm.nih.gov/33643776/
169. Allergic reactions and anaphylaxis to LNP-based COVID-19

vaccines: https://pubmed.ncbi.nlm.nih.gov/33571463/
170. Reported orofacial adverse effects from COVID-19 vaccines: the known and the
unknown: https://pubmed.ncbi.nlm.nih.gov/33527524/
171. Cutaneous adverse effects of available COVID-19

172. Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA
vaccine (Pfizer-BioNTech) in Japan: the first month
report: https://pubmed.ncbi.nlm.nih.gov/34347278/
173. COVID-19 vaccines increase the risk of

anaphylaxis: https://pubmed.ncbi.nlm.nih.gov/33685103/
174. Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19
mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
175. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement
of polyethylene glycol and IgG-mediated complement
activation: https://pubmed.ncbi.nlm.nih.gov/33657648/
176. Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19
177. Acute allergic reactions to COVID-19 mRNA

178. Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young
adult recipient and management of future exposure to SARS-
CoV2: https://pubmed.ncbi.nlm.nih.gov/33919151/
179. Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine
against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval
safety data: https://pubmed.ncbi.nlm.nih.gov/34128049/
180. Allergic reactions and adverse events associated with administration of mRNA-based
vaccines. A health system experience: https://pubmed.ncbi.nlm.nih.gov/34474708/
181. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and
Clinical Immunology
(BelSACI): https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447
182. .IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19

mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34318537/
183. Allergic reactions after COVID-19 vaccination: putting the risk in

perspective: https://pubmed.ncbi.nlm.nih.gov/34463751/
184. Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies:
https://pubmed.ncbi.nlm.nih.gov/33846043/ 188.
185. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin
disease: practical recommendations. An ETFAD position statement with external
experts: https://pubmed.ncbi.nlm.nih.gov/33752263/
186. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility
diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/
187. Fatal brain hemorrhage after COVID-19

188. A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at
Loma Linda University: https://pubmed.ncbi.nlm.nih.gov/34423106/
189. Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based
on a registry of 414 cases: https://pubmed.ncbi.nlm.nih.gov/33838206/
190. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-
REPP: a registry-based study: https://pubmed.ncbi.nlm.nih.gov/34517079/
191. Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-
sectional study of 405 cases: https://pubmed.ncbi.nlm.nih.gov/34254291/
192. Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-
19: review of 40 cases in an international dermatologic
registry: https://pubmed.ncbi.nlm.nih.gov/34487581/
193. Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19
vaccine: diagnostic and therapeutic recommendations for a new
syndrome: https://pubmed.ncbi.nlm.nih.gov/33987882/
194. Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune)

thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34138513/
195. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after

COVID-19 vaccination: the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/34402235/
196. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive
SARS-CoV-2 tests: self-controlled case series
study: https://pubmed.ncbi.nlm.nih.gov/34446426/
197. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus

thrombosis after covid-19 vaccination; a systematic
review: https://pubmed.ncbi.nlm.nih.gov/34365148/.
198. Nerve and muscle adverse events after vaccination with COVID-19: a systematic review
and meta-analysis of clinical trials: https://pubmed.ncbi.nlm.nih.gov/34452064/.
199. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation
temporally associated with administration of COVID-19
200. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia

induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine
(VITT): https://pubmed.ncbi.nlm.nih.gov/34256983/
201. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the
COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.
202. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after

administration of AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34132839/
203. 59-year-old woman with extensive deep venous thrombosis and pulmonary
thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-
204. Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-

AstraZeneca COVID-19: a missed opportunity for a rapid return on
experience: https://pubmed.ncbi.nlm.nih.gov/34033927/
205. Myocarditis and other cardiovascular complications of mRNA-based COVID-19

206. Pericarditis after administration of COVID-19 mRNA BNT162b2

207. Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-
1237 Modern: https://pubmed.ncbi.nlm.nih.gov/34447639/
208. Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine
mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34514306/
209. Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after

mRNA/DNA vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/33946748/
210. Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine:
could accidental intravenous injection of a vaccine induce
myopericarditis: https://pubmed.ncbi.nlm.nih.gov/34453510/
211. Immune thrombocytopenia in a 22-year-old post Covid-19
212. propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after

COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34451967/
213. Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine:
case report: https://pubmed.ncbi.nlm.nih.gov/34377889/
214. Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1

nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in
Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
215. COVID-19 vaccination association and facial nerve palsy: A case-control

216. The association between COVID-19 vaccination and Bell’s

palsy: https://pubmed.ncbi.nlm.nih.gov/34411533/
217. Bell’s palsy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33611630/
218. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated
ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine
(AZD1222): https://pubmed.ncbi.nlm.nih.gov/33981305/
219. Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273

220. Sequential contralateral facial nerve palsy after first and second doses of COVID-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/34281950/.
221. Transverse myelitis induced by SARS-CoV-2

222. Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-
19): https://pubmed.ncbi.nlm.nih.gov/33734623/
223. Acute abducens nerve palsy after COVID-19

vaccination: https://pubmed.ncbi.nlm.nih.gov/34044114/.
224. Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-
report database: https://pubmed.ncbi.nlm.nih.gov/34492394/
225. Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for
SARS-CoV-2 diplopia after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34369471/
226. Bell’s palsy after Ad26.COV2.S COVID-19

227. Bell’s palsy after COVID-19 vaccination: case

228. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy
following ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34272622/
229. Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-
230. Acute facial paralysis as a possible complication of SARS-CoV-2

231. Bell’s palsy after COVID-19 vaccination with high antibody response in
CSF: https://pubmed.ncbi.nlm.nih.gov/34322761/.
232. Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination.

Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve
palsy” by Coll et al. Articular Spine 2021; 88:
10519: https://pubmed.ncbi.nlm.nih.gov/34139321/.
233. Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case
report: https://pubmed.ncbi.nlm.nih.gov/34032902/.
234. Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19):
causality or victim?: https://pubmed.ncbi.nlm.nih.gov/33862041/
235. Autoimmune hepatitis triggered by vaccination against SARS-CoV-

236. Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after

vaccination with COVID-19 mRNA: a new clinical
entity: https://pubmed.ncbi.nlm.nih.gov/34293683/.
237. Autoimmune hepatitis after COVID

238. A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with
Janssen COVID-19: https://pubmed.ncbi.nlm.nih.gov/34449715/
239. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and

Ad26.COV.2.S vaccines: https://pubmed.ncbi.nlm.nih.gov/34139631/.
240. Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune
thrombocytopenia after vaccination with ChAdOx1 nCoV-
241. Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced
immune-immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33914590/
242. Venous sinus thrombosis after vaccination with ChAdOx1 nCov-

243. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis
of cases reported to the European Medicines
Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
244. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive
SARS-CoV-2 tests: self-controlled case series
245. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis
of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/
246. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after

vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based
cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
thromboembolic and hemorrhagic events in
Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/
248. Cerebral venous thrombosis associated with COVID-19 vaccine in

Germany: https://pubmed.ncbi.nlm.nih.gov/34288044/
249. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic
variant of vaccine-induced immune-mediated thrombotic
250. celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after
the first dose of Oxford vaccine, causal relationship or
coincidence: https://pubmed.ncbi.nlm.nih.gov/34261633/.
251. Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19

(VITT) vaccine-induced immune thrombotic
252. Thrombocytopenia after COVID-19

253. Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19
254. Thrombosis with thrombocytopenia syndrome after COVID-19

immunization: https://pubmed.ncbi.nlm.nih.gov/34236343/
255. Acute myocardial infarction within 24 hours after COVID-19

256. Bilateral acute macular neuroretinopathy after SARS-CoV-2

257. central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA
vaccination: are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
258. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after
COVID-19 vaccination: the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/34402235/
thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian
male treated with conventional heparin-warfarin-based
anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
260. Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA
261. A case of multiple thrombocytopenia and thrombosis following vaccination with

ChAdOx1 nCoV-19 against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34137813/
262. Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis

and adenovirus-based SARS-CoV-2 vaccines: https://pubmed.ncbi.nlm.nih.gov/34191218/
263. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by

ChAdOx1 nCov-19 vaccine: impact on recanalization
strategy: https://pubmed.ncbi.nlm.nih.gov/34175640/
264. New-onset refractory status epilepticus after ChAdOx1 nCoV-19

265. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector
266. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson &
Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
267. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after

administration of the AstraZeneca COVID-19
268. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-
induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34144250/
269. Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2
mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/33687691/
270. Procoagulant antibody-mediated procoagulant platelets in immune thrombotic

thrombocytopenia associated with SARS-CoV-2
271. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of

cerebral venous thrombosis with high mortality rate: a case
series: https://pubmed.ncbi.nlm.nih.gov/34393988/.
272. Procoagulant microparticles: a possible link between vaccine-induced immune

thrombocytopenia (VITT) and cerebral sinus venous
thrombosis: https://pubmed.ncbi.nlm.nih.gov/34129181/.
273. Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data from
the French network of regional pharmacovigilance
centers: https://pubmed.ncbi.nlm.nih.gov/34083026/.
274. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the
275. Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal

haemorrhage: https://pubmed.ncbi.nlm.nih.gov/34235757/.
276. Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19

277. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-

AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/
278. Cerebral venous thrombosis following COVID-19

279. Lipschütz ulcers after AstraZeneca COVID-19

280. Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-

281. Thrombosis with thrombocytopenia after Messenger vaccine RNA-

282. Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-
283. Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the

underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34071883/
284. Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia

285. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using
the EudraVigilance database: Thrombosis in unusual
sites: https://pubmed.ncbi.nlm.nih.gov/34375510/
286. Immunoglobulin adjuvant for vaccine-induced immune thrombotic

287. Severe vaccine-induced thrombotic thrombocytopenia following vaccination with

COVID-19: an autopsy case report and review of the
literature: https://pubmed.ncbi.nlm.nih.gov/34355379/.
288. A case of acute pulmonary embolism after immunization with SARS-CoV-2

289. Neurosurgical considerations regarding decompressive craniectomy for intracerebral
hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-
VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/
290. Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic

thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/.
291. Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease

associated with the BNT162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105247/.
292. Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced

293. Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two
cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34416410/.
294. Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222)

295. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after
anti-SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34224024/.
296. Post-vaccinal encephalitis after ChAdOx1 nCov-

297. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine:

cause or coincidence?: https://pubmed.ncbi.nlm.nih.gov/34507266/
298. Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with
multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/34459725/
299. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-
300. Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA
syndrome: https://pubmed.ncbi.nlm.nih.gov/34043800/.
301. Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the
Ad26.COV2.S vaccine: https://pubmed.ncbi.nlm.nih.gov/34447646/
302. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large
population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.
303. fulminant myocarditis and systemic hyperinflammation temporally associated with

BNT162b2 COVID-19 mRNA vaccination in two
patients: https://pubmed.ncbi.nlm.nih.gov/34416319/.
304. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered
on cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
305. Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus
after mRNA- or adenoviral vector-based SARS-CoV-2
306. Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA
(mRNA)-based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34513435/
307. Hepatitis C virus reactivation after COVID-19 vaccination: a case

308. Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2

recombinant viral vector vaccine: https://pubmed.ncbi.nlm.nih.gov/34483273/.
309. Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine

in an elderly woman: https://pubmed.ncbi.nlm.nih.gov/34513446/
310. Platelet activation and modulation in thrombosis with thrombocytopenia syndrome

associated with the ChAdO × 1 nCov-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34474550/
311. Reactive arthritis after COVID-19

312. Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune /

inflammatory syndrome induced by adjuvants: https://pubmed.ncbi.nlm.nih.gov/33858208/
313. Acute relapse and impaired immunization after COVID-19 vaccination in a patient with
multiple sclerosis treated with rituximab: https://pubmed.ncbi.nlm.nih.gov/34015240/
314. Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-
315. COVID-19 mRNA vaccine causing CNS inflammation: a case

series: https://pubmed.ncbi.nlm.nih.gov/34480607/
316. Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-

317. Acute disseminated encephalomyelitis following vaccination against SARS-CoV-

318. Tolosa-Hunt syndrome occurring after COVID-19

319. Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19
(Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
320. Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen;

Johnson & Johnson): https://pubmed.ncbi.nlm.nih.gov/34469919/.
321. Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after

vaccination with Ad26.COV2.S: case report: https://pubmed.ncbi.nlm.nih.gov/34516272/.
322. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic
response to methylprednisolone: case report: https://pubmed.ncbi.nlm.nih.gov/34512961/
323. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19
324. Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-

AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34171435/
325. Severe relapse of multiple sclerosis after COVID-19 vaccination: a case

326. Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector
Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34514078/
327. Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-

328. IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-
329. A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case
330. Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-
AstraZeneca / Covishield): report of two cases: https://pubmed.ncbi.nlm.nih.gov/34350668/
331. Hailey-Hailey disease exacerbation after SARS-CoV-2

332. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up

by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/.
333. COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity:

concern in cases with underlying hepatic
problems: https://pubmed.ncbi.nlm.nih.gov/34509271/.
334. Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous
thrombosis after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34462996/
335. Immune thrombocytopenia after vaccination during the COVID-19

pandemic: https://pubmed.ncbi.nlm.nih.gov/34435486/
336. COVID-19: lessons from the Norwegian tragedy should be taken into account in planning
for vaccine launch in less developed/developing
countries: https://pubmed.ncbi.nlm.nih.gov/34435142/
337. Rituximab-induced acute lympholysis and pancytopenia following vaccination with

COVID-19: https://pubmed.ncbi.nlm.nih.gov/34429981/
338. Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2
vaccines: report of two cases: https://pubmed.ncbi.nlm.nih.gov/34427024/
339. Vaccine-induced interstitial lung disease: a rare reaction to COVID-19

340. Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four
cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34236711/
341. Vaccine-induced thrombocytopenia with severe

headache: https://pubmed.ncbi.nlm.nih.gov/34525282/
342. Acute perimyocarditis after the first dose of COVID-19 mRNA

343. Rhabdomyolysis and fasciitis induced by COVID-19 mRNA

344. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the
literature: https://pubmed.ncbi.nlm.nih.gov/34363637/
345. Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA

vaccine BNT162b2: https://www.sciencedirect.com/science/article/pii/S2214250921002018
346. Secondary immune thrombocytopenia putatively attributable to COVID-19

vaccination: https://casereports.bmj.com/content/14/5/e242220.abstract.
347. Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19

348. Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine

administration: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/.
349. Idiopathic thrombocytopenic purpura and the Modern Covid-19

vaccine: https://www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext.
350. Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -

2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/.
351. Immune thrombocytopenic purpura and acute liver injury after COVID-19
vaccination: https://casereports.bmj.com/content/14/7/e242678.
352. Collection of complement-mediated and autoimmune-mediated hematologic conditions

after SARS-CoV-2
vaccination: https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmun
e-and-complement-mediated-hematologic
353. Petechial rash associated with CoronaVac vaccination: first report of cutaneous side
effects before phase 3 results: https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-
2021-002794
354. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal
hemoglobinuria: https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-
vaccines-induce-severe-hemolysis-in
355. Cerebral venous thrombosis associated with COVID-19 vaccine in

Germany: https://pubmed.ncbi.nlm.nih.gov/34288044/.
356. Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and
radiological management: https://pubmed.ncbi.nlm.nih.gov/34327553/.
357. Cerebral venous thrombosis and thrombocytopenia after COVID-19

358. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination:
report of two cases in the United Kingdom: https://pubmed.ncbi.nlm.nih.gov/33857630/.
359. Cerebral venous thrombosis induced by SARS-CoV-2

360. Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine:

case report: https://pubmed.ncbi.nlm.nih.gov/34312301/.
361. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic

362. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced

immune-immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34455073/
363. Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2

364. Cerebral venous thrombosis after COVID-19

365. Lethal cerebral venous sinus thrombosis after COVID-19

366. Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination
with adenovirus and after COVID-19: https://pubmed.ncbi.nlm.nih.gov/34116145/
367. Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis
increased by intravascular administration of the
368. Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA
vaccination: are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
369. Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading
first brain MRI: https://pubmed.ncbi.nlm.nih.gov/34244448/
370. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral
venous sinus thrombosis after vaccination with
371. Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia

by COVID-19: https://pubmed.ncbi.nlm.nih.gov/33845870/.
372. Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA
373. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of

cerebral venous thrombosis with a high mortality rate: a case
374. Adenovirus interactions with platelets and coagulation and vaccine-associated

autoimmune thrombocytopenia thrombosis
syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/.
375. Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the

ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort
376. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on
cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
377. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis
of cases reported to the European Medicines
Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
378. A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19
AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34274191/
thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian
male treated with conventional heparin-warfarin-based
anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
380. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after

vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based
cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
381. Procoagulant microparticles: a possible link between vaccine-induced immune

thrombocytopenia (VITT) and cerebral sinus venous
thrombosis: https://pubmed.ncbi.nlm.nih.gov/34129181/
382. S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after
vaccination with Ad26.COV2.S, March 2-April 21,
383. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic
variant of vaccine-induced immune-mediated thrombotic
384. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by

ChAdOx1 nCov-19 vaccine: impact on recanalization
strategy: https://pubmed.ncbi.nlm.nih.gov/34175640/
385. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new

clinicopathologic entity with heterogeneous clinical
presentations: https://pubmed.ncbi.nlm.nih.gov/34159588/.
386. Imaging and hematologic findings in thrombosis and thrombocytopenia after

vaccination with ChAdOx1 nCoV-19 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34402666/
387. Autoimmunity roots of thrombotic events after vaccination with COVID-

388. Cerebral venous sinus thrombosis after vaccination: the UK

389. Massive cerebral venous thrombosis and venous basin infarction as late complications
of COVID-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34373991/
390. Australian and New Zealand approach to the diagnosis and treatment of vaccine-
induced immune thrombosis and immune
391. An observational study to identify the prevalence of thrombocytopenia and anti-PF4 /

polyanion antibodies in Norwegian health care workers after COVID-19
392. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated
ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222)
393. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after
ChAdOx1 nCoV-19 vaccine:. https://pubmed.ncbi.nlm.nih.gov/34272622/
394. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently
vaccinated with an adenoviral vector-based COVID-19
vaccine:. https://pubmed.ncbi.nlm.nih.gov/33877737/
395. Predicted and observed incidence of thromboembolic events among Koreans vaccinated
with the ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34254476/
thromboembolic, and hemorrhagic events in
Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/
397. ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune
thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in
Thailand: https://pubmed.ncbi.nlm.nih.gov/34483267/.
398. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson &
Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
399. Neurosurgical considerations with respect to decompressive craniectomy for

intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic
thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/
400. Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case
401. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-
402. A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after
ChAdOx1 nCoV-19 vaccination against SARS-CoV-
403. Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-
induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/.
404. Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced

thrombotic immune thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34268278/.
405. Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine
(Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic
406. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large
population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.
407. Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage

and hematoma after minor oral surgery: https://pubmed.ncbi.nlm.nih.gov/34314875/.
408. Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1
nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34384129/
409. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia

syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for
monitoring immunoglobulin G levels: https://pubmed.ncbi.nlm.nih.gov/34382387/
410. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2

vaccination: victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/.
411. Intracerebral hemorrhage associated with vaccine-induced thrombotic

thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant
woman: https://pubmed.ncbi.nlm.nih.gov/34261297/
412. Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic
413. Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-

414. A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive

arteriovenous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34059191/
415. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-

AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/
416. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19

417. Vaccine-induced thrombocytopenia with severe

headache: https://pubmed.ncbi.nlm.nih.gov/34525282/
418. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17

years: stratified analysis of a national
database: https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1
419. COVID-19 mRNA vaccination and development of CMR-confirmed

myopericarditis: https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09.
420. Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA

vaccine: https://onlinelibrary.wiley.com/doi/10.1111/trf.16672
421. Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce
acute myopericarditis in a mouse model: https://t.co/j0IEM8cMXI
422. A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting
System. (VAERS) in association with COVID-19 injectable
biologics: https://pubmed.ncbi.nlm.nih.gov/34601006/
423. This study concludes that: “The vaccine was associated with an excess risk of
myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse
event and of many other serious adverse events increased substantially after SARS-CoV-2
infection”: https://www.nejm.org/doi/full/10.1056/NEJMoa2110475
424. Bilateral uveitis after inoculation with COVID-19 vaccine: a case

425. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17

years: stratified analysis of a national
database: https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1.
426. Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but
confirmed: https://www.sciencedirect.com/science/article/pii/S0168827821020936
427. Extensive investigations revealed consistent pathophysiologic alterations after
vaccination with COVID-19 vaccines: https://www.nature.com/articles/s41421-021-00329-3
428. Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-
based SARS-CoV-2 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/
429. Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk
of Acute Coronary Syndrome as measured by PULS cardiac testing: a
caution: https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712
430. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with
thrombocytopenia syndrome:https://www.science.org/doi/10.1126/sciadv.abl8213
431. Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following

announcement 26.COV2.S: first documented case outside the
U.S.: https://pubmed.ncbi.nlm.nih.gov/34626338/
432. A prothrombotic thrombocytopenic disorder resembling heparin-induced

thrombocytopenia after coronavirus-19
vaccination: https://europepmc.org/article/PPR/PPR304469 435.
433. VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with

ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34731555/
434. Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic

entity with heterogeneous clinical presentations: https://pubmed.ncbi.nlm.nih.gov/34159588/
435. Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced
immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34461442/
436. Spectrum of neurological complications after COVID-19

437. Cerebral venous sinus thrombosis after vaccination: the UK

438. Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after
439. Portal vein thrombosis due to vaccine-induced immune thrombotic immune

thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-
440. Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca
ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34620638/
441. Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-
19 in a hemodialysis patient: https://pubmed.ncbi.nlm.nih.gov/34650896/
442. Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-

443. Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and
BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with
teriflunomide: https://pubmed.ncbi.nlm.nih.gov/34696248/
444. Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case

445. Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with

delayed therapeutic plasma exchange (TPE): https://pubmed.ncbi.nlm.nih.gov/34672380/.
446. Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus
447. Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced
cerebral venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34535076/.
448. Clinical features of vaccine-induced thrombocytopenia and immune

449. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19

vaccination: the FAPIC score: https://pubmed.ncbi.nlm.nih.gov/34545400/
450. Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia

induced by ChAdOx1-nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34035134/
451. In-hospital observational study of neurological disorders in patients recently vaccinated

with COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34688190/
452. Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and
thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three
cases: https://pubmed.ncbi.nlm.nih.gov/34782400/
453. Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2,
ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European
data: https://pubmed.ncbi.nlm.nih.gov/34710832/
454. Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS
and more: https://pubmed.ncbi.nlm.nih.gov/34695859/
455. Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of

74 consecutive cases: https://pubmed.ncbi.nlm.nih.gov/34453762/.
456. Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-

BioNTech: https://pubmed.ncbi.nlm.nih.gov/34660652/.
457. Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with
ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical
thrombectomy: https://pubmed.ncbi.nlm.nih.gov/34644642/
458. Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching

hospital: https://pubmed.ncbi.nlm.nih.gov/34694650/
459. Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by
ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34726934/
460. Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a
population-based study in Italy: https://pubmed.ncbi.nlm.nih.gov/34835237/
461. Intracerebral hemorrhage associated with vaccine-induced thrombotic

thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant
462. Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with
Ad26.COV2.S COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34724036/.
463. Genital necrosis with cutaneous thrombosis following vaccination with COVID-19
464. Cerebral venous sinus thrombosis after mRNA-based COVID-19

465. COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis

(VITT) and shades of gray in thrombus formation: https://pubmed.ncbi.nlm.nih.gov/34624910/
466. Inflammatory myositis after vaccination with

ChAdOx1: https://pubmed.ncbi.nlm.nih.gov/34585145/
467. Acute ST-segment elevation myocardial infarction secondary to vaccine-induced

immune thrombosis with thrombocytopenia
(VITT): https://pubmed.ncbi.nlm.nih.gov/34580132/.
468. A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting

the venosplanchnic and pulmonary arterial circulation from a UK district general
hospital: https://pubmed.ncbi.nlm.nih.gov/34535492/
469. COVID-19 vaccine-induced thrombotic thrombocytopenia: a case

470. Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca
ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit
analysis for people <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
471. Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine

(AstraZeneca), Victoria, Australia: https://pubmed.ncbi.nlm.nih.gov/34756770/
472. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in
thrombotic immune thrombocytopenia induced by SARS-CoV-2
vaccine: https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622
473. Case study of thrombosis and thrombocytopenia syndrome after administration of the
AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34781321/
474. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19
Vaccines: https://pubmed.ncbi.nlm.nih.gov/34062319/
475. Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of
definite thrombosis with thrombocytopenia syndrome in
India: https://pubmed.ncbi.nlm.nih.gov/34706921/
476. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS):

systematic review and post hoc analysis: https://pubmed.ncbi.nlm.nih.gov/34698582/.
477. Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-
478. Acute transverse myelitis after COVID-19

479. Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-
vectored COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34541935/
480. Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case

481. Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic
management: https://pubmed.ncbi.nlm.nih.gov/34327553/.
482. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently
vaccinated with an adenoviral vector-based COVID-19
483. Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine:

clinical and diagnostic challenges of vaccine-induced thrombotic
484. Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca
COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34242687/.
485. Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-
2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34609603/
486. Case report: Pityriasis rosea-like rash after vaccination with COVID-
487. Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case
488. Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine

AZD1222: https://pubmed.ncbi.nlm.nih.gov/34812326/.
489. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19

mRNA vaccines reported to the Vaccine Adverse Event Reporting System
(VAERS): https://pubmed.ncbi.nlm.nih.gov/34006408/
490. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2
vaccination: victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/
491. Vaccine-induced immune thrombosis and thrombocytopenia syndrome after

adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new
hypothesis on mechanisms and implications for future vaccine
development: https://pubmed.ncbi.nlm.nih.gov/34664303/.
492. Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following

adenoviral COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34649281/.
493. Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus

disease 2019 vaccination: https://pubmed.ncbi.nlm.nih.gov/34420249/
494. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19
vaccines: systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/34610990/.
495. Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly

496. Sudden sensorineural hearing loss after COVID-19

497. Prevalence of serious adverse events among health care professionals after receiving
the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March
498. Acute hemichorea-hemibalismus after COVID-19 (AZD1222)

499. Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in
Italy: https://pubmed.ncbi.nlm.nih.gov/34741583/
500. Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case
501. Thrombosis after COVID-19 vaccination: possible link to ACE

pathways: https://pubmed.ncbi.nlm.nih.gov/34479129/
502. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19

503. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus

vaccine nCoV-19 (recombinant): https://pubmed.ncbi.nlm.nih.gov/34546608/
504. Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic
thrombocytopenia induced by COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34546343/
505. Longitudinally extensive cervical myelitis after vaccination with inactivated virus based
COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34849183/
506. Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19
507. A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19
(AZD1222): https://pubmed.ncbi.nlm.nih.gov/34751429/.
508. Ocular adverse events following COVID-19

509. Depression after ChAdOx1-S / nCoV-19

510. Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19

511. Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19

vaccination: a case series of two patients: https://pubmed.ncbi.nlm.nih.gov/34755433/
512. Major artery thrombosis and vaccination against ChAdOx1 nCov-

513. Rare case of contralateral supraclavicular lymphadenopathy after vaccination with

COVID-19: computed tomography and ultrasound
findings: https://pubmed.ncbi.nlm.nih.gov/34667486/
514. Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222
(Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or
causality: https://pubmed.ncbi.nlm.nih.gov/34726187/.
515. Pancreas allograft rejection after ChAdOx1 nCoV-19

516. Understanding the risk of thrombosis with thrombocytopenia syndrome following

Ad26.COV2.S vaccination: https://pubmed.ncbi.nlm.nih.gov/34595694/
517. Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca
vaccine COVID-19: a prospective cohort study in health care
workers: https://pubmed.ncbi.nlm.nih.gov/34661934/
518. Comments on thrombosis after vaccination: spike protein leader sequence could be
responsible for thrombosis and antibody-mediated
thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34788138
519. Eosinophilic dermatosis after AstraZeneca COVID-19

520. Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases
and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34653943/.
521. Relapse of immune thrombocytopenia after COVID-19

522. Thrombosis in pre- and post-vaccination phase of COVID-
19; https://pubmed.ncbi.nlm.nih.gov/34650382/
523. A look at the role of postmortem immunohistochemistry in understanding the

inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse
events: a narrative review: https://pubmed.ncbi.nlm.nih.gov/34769454/
524. COVID-19 vaccine in patients with hypercoagulability disorders: a clinical

perspective: https://pubmed.ncbi.nlm.nih.gov/34786893/
525. Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading

to combined venous micro-macrothrombosis: https://pubmed.ncbi.nlm.nih.gov/34833382/
526. Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid

occlusion after COVID-19 Ad26.COV2.S vaccine
(Janssen): https://pubmed.ncbi.nlm.nih.gov/34670287/
527. An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine:
528. Immediate high-dose intravenous immunoglobulins followed by direct treatment with

thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic
thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral
sinus and portal vein: https://pubmed.ncbi.nlm.nih.gov/34023956/.
529. Thrombosis formation after COVID-19 vaccination immunologic aspects: review

article: https://pubmed.ncbi.nlm.nih.gov/34629931/
530. Imaging and hematologic findings in thrombosis and thrombocytopenia after

vaccination with ChAdOx1 nCoV-19 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34402666/
531. Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and

review of the literature: https://pubmed.ncbi.nlm.nih.gov/34842783/
532. Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after
COVID-19 vaccination in a Taiwanese man: a case report and review of the
literature: https://pubmed.ncbi.nlm.nih.gov/34630307/
533. Fatal cerebral venous sinus thrombosis after COVID-19

534. Autoimmune roots of thrombotic events after COVID-19

535. New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or

COVID-19: https://www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext.
536. Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca®

537. Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of
BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34796065/.
538. Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in

health care workers taking ACE inhibitors: https://pubmed.ncbi.nlm.nih.gov/34579248/
539. A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune

thrombotic thrombocytopenia with splanchnic vein
thrombosis: https://pubmed.ncbi.nlm.nih.gov/34843991/
540. Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19
(BNT162b2): https://pubmed.ncbi.nlm.nih.gov/34595867/
541. A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19

BNT162b2 vaccine (Pfizer-Biontech): https://pubmed.ncbi.nlm.nih.gov/34820240/
542. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting

pathologic mechanisms with Bruton’s tyrosine kinase
inhibitors: https://pubmed.ncbi.nlm.nih.gov/33851389/
543. Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-

S: https://pubmed.ncbi.nlm.nih.gov/33980419/
544. Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna

COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34264151/
545. Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca
in women receiving estrogen: https://pubmed.ncbi.nlm.nih.gov/34734086/
546. Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying

disease: https://pubmed.ncbi.nlm.nih.gov/34755555/
547. Adenovirus interactions with platelets and coagulation and vaccine-induced immune
thrombotic thrombocytopenia syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/
548. Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2

549. Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019
coronavirus disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34840204/
550. Neurological side effects of SARS-CoV-2

551. Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of
SARS-CoV-2 spike protein and adenovirus vector-activated signaling
pathways: https://pubmed.ncbi.nlm.nih.gov/34639132/
552. Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of
acute pulmonary embolism complications and follow-
up: https://pubmed.ncbi.nlm.nih.gov/34804412/
553. Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case
554. Complicated case report of long-term vaccine-induced thrombotic immune

thrombocytopenia A: https://pubmed.ncbi.nlm.nih.gov/34835275/.
555. Deep venous thrombosis after vaccination with Ad26.COV2.S in adult

males: https://pubmed.ncbi.nlm.nih.gov/34659839/.
556. Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case

557. Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA
558. Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine

(recombinant): https://pubmed.ncbi.nlm.nih.gov/34528522/
559. Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer

in Thais after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34568726/
560. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-

vaccination: https://academic.oup.com/cid/advance-article-
abstract/doi/10.1093/cid/ciab989/644 5179.
561. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and
determination of incidence rate: https://academic.oup.com/cid/advance-
article/doi/10.1093/cid/ciab926/6420408
562. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine
types: https://www.mdpi.com/2075-4426/11/11/1106
563. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of

COVID-19 mRNA vaccine in Korean children: a multicenter
564. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-
COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
565. Myocarditis Following mRNA COVID-19 Vaccine: https://journals.lww.com/pec-

online/Abstract/2021/11000/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx.
566. Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in

Israel: https://pubmed.ncbi.nlm.nih.gov/34614328/.
567. Myocarditis, pericarditis, and cardiomyopathy following COVID-19

vaccination: https://www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext
568. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19

569. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR
Findings: https://pubmed.ncbi.nlm.nih.gov/34246586/
570. Hypersensitivity Myocarditis and COVID-19

Vaccines: https://pubmed.ncbi.nlm.nih.gov/34856634/.
571. Severe myocarditis associated with COVID-19 vaccine: zebra or

unicorn?: https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-
7/fulltext.
572. Acute myocardial infarction and myocarditis after COVID-19

vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/
573. Myocarditis after Covid-19 vaccination in a large healthcare

organization: https://www.nejm.org/doi/10.1056/NEJMoa2110737
574. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case
series of children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
575. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in

adolescents and young
adults: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=Z
39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
576. STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA
vaccination:. https://pubmed.ncbi.nlm.nih.gov/34756746/
577. Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from
a regional pharmacovigilance
center: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/
578. Myocarditis after COVID-19 mRNA

vaccines: https://pubmed.ncbi.nlm.nih.gov/34546329/.
579. Patients with acute myocarditis after COVID-19 mRNA

vaccination:. https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602.
580. Myocarditis after COVID-19 vaccination: a case

series: https://www.sciencedirect.com/science/article/pii/S0264410X21011725?via%3Dihub.
581. Myocarditis associated with COVID-19 vaccination in

adolescents: https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357
582. Myocarditis findings on cardiac magnetic resonance imaging after vaccination with
COVID-19 mRNA in adolescents:. https://pubmed.ncbi.nlm.nih.gov/34704459/
583. Myocarditis after COVID-19 vaccination: magnetic resonance imaging

study: https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230/6
421640.
584. Acute myocarditis after administration of the second dose of BNT162b2 COVID-19
vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/
585. Myocarditis after COVID-19

586. Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with
arrhythmogenic left ventricular cardiomyopathy: https://pubmed.ncbi.nlm.nih.gov/34712717/.

19: https://www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administration-
bnt162b2-S188558572100133X.
588. Myocarditis associated with COVID-19 mRNA

vaccination: https://pubs.rsna.org/doi/10.1148/radiol.2021211430
589. Acute myocarditis after COVID-19 vaccination: a case

590. Acute myopericarditis after COVID-19 vaccination in

adolescents:. https://pubmed.ncbi.nlm.nih.gov/34589238/.

vaccination: https://academic.oup.com/jpids/article/10/10/962/6329543.
592. Acute myocarditis associated with anti-COVID-19

vaccination: https://ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196.
593. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and
MRI findings:. https://pubmed.ncbi.nlm.nih.gov/34428917/.
594. Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19

vaccination:. https://pubmed.ncbi.nlm.nih.gov/34088762/.
595. Myocarditis and pericarditis in adolescents after first and second doses of COVID-19
mRNA vaccines:. https://academic.oup.com/ehjqcco/advance-
article/doi/10.1093/ehjqcco/qcab090/64 42104.
596. COVID 19 vaccine for adolescents. Concern for myocarditis and

pericarditis: https://www.mdpi.com/2036-7503/13/3/61.
597. Cardiac imaging of acute myocarditis after vaccination with COVID-19

598. Myocarditis temporally associated with COVID-19

599. Acute myocardial injury after COVID-19 vaccination: a case report and review of current
evidence from the vaccine adverse event reporting system
600. Acute myocarditis associated with COVID-19 vaccination: report of a
case: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/
601. Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case
602. Myocarditis in the setting of a recent COVID-19

603. Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two
cases: https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext.
604. Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer

in Thais after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34568726/

vaccination: https://academic.oup.com/cid/advance-article-
abstract/doi/10.1093/cid/ciab989/6445179
606. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence
rate determination: https://academic.oup.com/cid/advance-
article/doi/10.1093/cid/ciab926/6420408.
607. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine
types: https://www.mdpi.com/2075-4426/11/11/1106
608. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of

COVID-19 mRNA vaccine in Korean children: a multicenter
609. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-
COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
610. Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine:

611. Three cases of acute venous thromboembolism in women after coronavirus 2019
612. Clinical and biological features of cerebral venous sinus thrombosis after vaccination
with ChAdOx1 nCov-19; https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340.
613. COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus
thrombosis in a young man with normal platelet
count: https://pubmed.ncbi.nlm.nih.gov/34632750/
614. Post-mortem findings in vaccine-induced thrombotic

thrombocytopenia: https://haematologica.org/article/view/haematol.2021.279075
615. COVID-19 vaccine-induced thrombosis: https://pubmed.ncbi.nlm.nih.gov/34802488/.
616. Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms
behind vaccine-induced immune thrombocytopenia and
617. Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA

618. Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford-

AstraZeneca COVID-19: a missed opportunity for rapid return on
experience: https://www.sciencedirect.com/science/article/pii/S235255682100093X
619. Occurrence of splenic infarction due to arterial thrombosis after vaccination with
COVID-19: https://pubmed.ncbi.nlm.nih.gov/34876440/
620. Deep venous thrombosis more than two weeks after COVID-19
621. Case report: Take a second look: Cerebral venous thrombosis related to Covid-19
vaccination and thrombotic thrombocytopenia
syndrome: https://pubmed.ncbi.nlm.nih.gov/34880826/
622. Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic

623. Change in blood viscosity after COVID-19 vaccination: estimation for persons with
underlying metabolic syndrome: https://pubmed.ncbi.nlm.nih.gov/34868465/
624. Management of a patient with a rare congenital limb malformation syndrome after
SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia
625. Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic
thrombocytopenia or a coincidence due to underlying risk
factors: https://pubmed.ncbi.nlm.nih.gov/34820232/.
626. Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S

successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and
thrombectomy: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258
627. Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case
628. Successful treatment of vaccine-induced immune immune thrombotic

thrombocytopenia in a 26-year-old female patient: https://pubmed.ncbi.nlm.nih.gov/34614491/
629. Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a

patient with pancreatic cancer after vaccination with messenger RNA-
630. Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease
vaccination (COVID-19): https://pubmed.ncbi.nlm.nih.gov/33624509/.
631. Squamous cell carcinoma of the lung with hemoptysis following vaccination with
tozinameran (BNT162b2, Pfizer-BioNTech): https://pubmed.ncbi.nlm.nih.gov/34612003/
632. Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man

presenting as acute venous thromboembolism: https://pubmed.ncbi.nlm.nih.gov/34096082/
633. Myocarditis associated with COVID-19 vaccination in three adolescent

boys: https://pubmed.ncbi.nlm.nih.gov/34851078/.
634. Cardiovascular magnetic resonance findings in young adult patients with acute
myocarditis after COVID-19 mRNA vaccination: a case
635. Perimyocarditis after vaccination with COVID-


637. Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in

Korea: case report focusing on histopathological
638. Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or
older: https://pubmed.ncbi.nlm.nih.gov/34605853/
639. Recurrence of acute myocarditis temporally associated with receipt of the 2019
coronavirus mRNA disease vaccine (COVID-19) in an adolescent
male: https://pubmed.ncbi.nlm.nih.gov/34166671/
640. Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19)
mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34744118/
641. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old

male: https://pubmed.ncbi.nlm.nih.gov/34334935/.
642. Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after
vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34746968/
643. Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an
accidental coincidence or rather a vaccination-associated autoimmune
myocarditis?”: https://pubmed.ncbi.nlm.nih.gov/34333695/.
644. Self-limited myocarditis presenting with chest pain and ST-segment elevation in
adolescents after vaccination with BNT162b2 mRNA
645. Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the
U.S. Military: https://pubmed.ncbi.nlm.nih.gov/34185045/
646. Myocarditis after BNT162b2 vaccination in a healthy

male: https://pubmed.ncbi.nlm.nih.gov/34229940/
647. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination:

Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/
648. Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA

649. Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19
vaccine manufactured by Moderna: https://pubmed.ncbi.nlm.nih.gov/34866106/
650. Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a
40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/
651. Multimodality imaging and histopathology in a young man presenting with fulminant
lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-
652. Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in
a young Korean male: https://pubmed.ncbi.nlm.nih.gov/34636504/
653. Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-
CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34367386/
654. Acute myocarditis in a young adult two days after vaccination with
Pfizer: https://pubmed.ncbi.nlm.nih.gov/34709227/
655. Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA
coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary
resuscitation: https://pubmed.ncbi.nlm.nih.gov/34778411/
656. Acute myocarditis after 2019 coronavirus disease

657. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-
1279 and BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34246585/
658. Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease
vaccine in adolescents: https://pubmed.ncbi.nlm.nih.gov/34228985/
659. Post-vaccination multisystem inflammatory syndrome in adults without evidence of

prior SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34852213/
660. Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus
disease: https://pubmed.ncbi.nlm.nih.gov/34866122/
661. Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273
662. Myocarditis following COVID-19 vaccination: MRI

study: https://pubmed.ncbi.nlm.nih.gov/34739045/.
663. Acute myocarditis after COVID-19 vaccination: case

report: https://docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e
664. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19
in a case series of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
665. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in

adolescents and young adults: https://pubmed.ncbi.nlm.nih.gov/34865500/
666. Myocarditis following vaccination with Covid-19 in a large healthcare

organization: https://pubmed.ncbi.nlm.nih.gov/34614329/
667. AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal

link: https://pubmed.ncbi.nlm.nih.gov/34560365/
668. COVID-19, Guillain-Barré and vaccineA dangerous

mix: https://pubmed.ncbi.nlm.nih.gov/34108736/.
669. Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case
report and review of reported cases: https://pubmed.ncbi.nlm.nih.gov/34796417/.
670. Guillain-Barre syndrome after BNT162b2 COVID-19

vaccine: https://link.springer.com/article/10.1007%2Fs10072-021-05523-5.
671. COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial

palsy: https://onlinelibrary.wiley.com/doi/10.1002/ana.26258.
672. Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed

Guillain-Barre syndrome, February-July
2021: https://jamanetwork.com/journals/jama/fullarticle/2785009
673. A case of Guillain-Barré syndrome after Pfizer COVID-19

674. Guillain-Barré syndrome associated with COVID-19

675. Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA

vaccine: https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708
676. Guillain-Barre syndrome after COVID-19 vaccination in an

adolescent: https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext.
677. Guillain-Barre syndrome after ChAdOx1-S / nCoV-19

678. Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case
679. Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19

patients: https://pubmed.ncbi.nlm.nih.gov/34644738/.
680. Guillain-Barre syndrome presenting with facial diplegia following vaccination with
COVID-19 in two patients: https://pubmed.ncbi.nlm.nih.gov/34649856/
681. A rare case of Guillain-Barré syndrome after COVID-19

682. Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19

683. COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side

effect: https://pubmed.ncbi.nlm.nih.gov/34484780/
684. Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case
report; https://pubmed.ncbi.nlm.nih.gov/34779385/.
685. Miller Fisher syndrome after Pfizer COVID-19

686. Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus

687. Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after
Vaxzevria COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261746/
688. Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first
689. A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1

antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine
(Pfizer): https://pubmed.ncbi.nlm.nih.gov/34871447/
690. Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup

disproportionality analysis in VigiBase: https://pubmed.ncbi.nlm.nih.gov/34579259/
691. A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination:

AMSAN: https://pubmed.ncbi.nlm.nih.gov/34370408/.
692. A rare variant of Guillain-Barré syndrome after vaccination with

Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34703690/.
693. Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous

vaccine-associated Guillain-Barré syndrome: https://pubmed.ncbi.nlm.nih.gov/34810163/
694. Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-
CoV-2 vaccines: https://onlinelibrary.wiley.com/doi/10.1002/ana.26218.
695. Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the
696. Variant Guillain-Barré syndrome occurring after SARS-CoV-2

697. Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-
CoV-2 mRNA-based vaccine: https://pubmed.ncbi.nlm.nih.gov/34722067/
698. Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary
occurrence, not a causal association: https://pubmed.ncbi.nlm.nih.gov/33968610/
699. SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also
by distal small fiber neuropathy: https://pubmed.ncbi.nlm.nih.gov/34525410/
700. Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after
AstraZeneca 2019 coronavirus disease vaccine: https://pubmed.ncbi.nlm.nih.gov/34808658/
701. Adverse event reporting and risk of Bell’s palsy after COVID-19
vaccination: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-
0/fulltext.
702. Bilateral facial nerve palsy and COVID-19 vaccination: causality or

coincidence: https://pubmed.ncbi.nlm.nih.gov/34522557/
703. Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case
704. Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of
recurrent Bell’s palsy: case report: https://pubmed.ncbi.nlm.nih.gov/34621891/
705. Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2
infection: https://pubmed.ncbi.nlm.nih.gov/34697502/
706. Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s
palsy: https://pubmed.ncbi.nlm.nih.gov/33858693/
707. Acute transverse myelitis following inactivated COVID-19

708. Acute transverse myelitis after COVID-19

709. A case of longitudinally extensive transverse myelitis following Covid-19

710. Post COVID-19 transverse myelitis; a case report with review of the
711. Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated
virus for COVID-19: https://pubmed.ncbi.nlm.nih.gov/34189662/
712. Neuromyelitis optica in a healthy woman after vaccination against severe acute
respiratory syndrome coronavirus 2 mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34660149/
713. Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse
myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-
CoV-2: https://pubmed.ncbi.nlm.nih.gov/34131771/
714. A case series of acute pericarditis after vaccination with COVID-19 in the context of
recent reports from Europe and the United States: https://pubmed.ncbi.nlm.nih.gov/34635376/
715. Acute pericarditis and cardiac tamponade after vaccination with Covid-
716. Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19
mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34849667/

718. Acute myopericarditis after COVID-19 vaccine in

adolescents: https://pubmed.ncbi.nlm.nih.gov/34589238/
719. Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-

720. Case report: symptomatic pericarditis post COVID-19

721. An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old

patient: https://pubmed.ncbi.nlm.nih.gov/34797392/
722. Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-

19): https://pubmed.ncbi.nlm.nih.gov/34862234/
723. Myocarditis after SARS-CoV-2 mRNA vaccination, a case

724. Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after
Oxford-AstraZeneca SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34848426/.
725. Immune-mediated disease outbreaks or new-onset disease in 27 subjects after

mRNA/DNA vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/33946748/
726. Post-mortem investigation of deaths after vaccination with COVID-19

727. Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19
728. Relapse of immune thrombocytopenia after covid-19 vaccination in young male

patient: https://pubmed.ncbi.nlm.nih.gov/34804803/.
729. Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-
BioNTech BNT16B2b2: https://pubmed.ncbi.nlm.nih.gov/34077572/
730. Retinal hemorrhage after SARS-CoV-2

731. Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal
failure and pulmonary hemorrhage can occur after COVID-19
732. Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case

733. Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced

SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34549178/.
734. Brain death in a vaccinated patient with COVID-19

infection: https://pubmed.ncbi.nlm.nih.gov/34656887/
735. Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA

736. Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2
mRNA-based SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34729467/.
737. A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2
738. Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A
post-vaccination reaction: https://pubmed.ncbi.nlm.nih.gov/34092400/742.
739. Severe immune thrombocytopenic purpura after SARS-CoV-2

740. Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2
patients with IgA nephropathy: https://pubmed.ncbi.nlm.nih.gov/33771584/
741. Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2

742. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility
diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/
743. Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-
CoV-2 vaccines: a case series and a nested case-control
744. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario,

Canada: by vaccine product, schedule, and
interval: https://www.medrxiv.org/content/10.1101/2021.12.02.21267156v1
745. Anaphylaxis following Covid-19 vaccine in a patient with cholinergic
urticaria: https://pubmed.ncbi.nlm.nih.gov/33851711/
746. Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of
revaccination: https://pubmed.ncbi.nlm.nih.gov/34675550/.
747. Anaphylaxis after Modern COVID-19

748. Association of self-reported history of high-risk allergy with allergy symptoms after
749. Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-

750. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech
COVID-19 vaccine – United States, December 14 to 23,
751. Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-
19 vaccine – United States, December 21, 2020 to January 10,
752. Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and
mechanism of action: https://pubmed.ncbi.nlm.nih.gov/33834172/
753. Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis

following vaccination with Pfizer BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34579211/
754. Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine
with positive polysorbate 80 skin test result: https://pubmed.ncbi.nlm.nih.gov/34343674/
755. Acute myocardial infarction and myocarditis after COVID-19

756. Takotsubo syndrome after COVID-19

757. Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on

maintenance hemodialysis: https://pubmed.ncbi.nlm.nih.gov/34731486/.
758. Premature myocardial infarction or side effect of COVID-19

759. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-
19 vaccine in persons aged 75 years or older: https://pubmed.ncbi.nlm.nih.gov/34807248/
760. Kounis syndrome type 1 induced by inactivated SARS-COV-2

761. Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis
syndrome the culprit: https://pubmed.ncbi.nlm.nih.gov/34702550/
762. Deaths associated with the recently launched SARS-CoV-2 vaccination

(Comirnaty®): https://pubmed.ncbi.nlm.nih.gov/33895650/
763. Deaths associated with recently launched SARS-CoV-2

764. A case of acute encephalopathy and non-ST-segment elevation myocardial infarction

after vaccination with mRNA-1273: possible adverse
effect: https://pubmed.ncbi.nlm.nih.gov/34703815/
765. COVID-19 vaccine-induced urticarial

vasculitis: https://pubmed.ncbi.nlm.nih.gov/34369046/.
766. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19

767. New-onset leukocytoclastic vasculitis after COVID-19

768. Cutaneous small vessel vasculitis after COVID-19

769. Outbreak of leukocytoclastic vasculitis after COVID-19

770. Leukocytoclastic vasculitis after exposure to COVID-19

771. Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc
ergo propter hoc?; https://pubmed.ncbi.nlm.nih.gov/34495381/.
772. Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA

vaccine: https://pubmed.ncbi.nlm.nih.gov/34327795
773. Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19

774. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic
Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19
775. Reactivation of IgA vasculitis after vaccination with COVID-

776. Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19

777. Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine
booster: https://pubmed.ncbi.nlm.nih.gov/34720009/
778. A rare case of Henoch-Schönlein purpura after a case report of COVID-19

779. Cutaneous vasculitis following COVID-19

780. Possible case of COVID-19 mRNA vaccine-induced small-vessel

vasculitis: https://pubmed.ncbi.nlm.nih.gov/34705320/.
781. IgA vasculitis following COVID-19 vaccination in an

adult: https://pubmed.ncbi.nlm.nih.gov/34779011/
782. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis

following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34451967/
783. Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and
neutrophil anti-cytoplasmic antibody-associated
vasculitis: https://pubmed.ncbi.nlm.nih.gov/33928459/
784. Reactivation of IgA vasculitis after COVID-19

785. Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19
786. First description of immune complex vasculitis after COVID-19 vaccination with
BNT162b2: case report: https://pubmed.ncbi.nlm.nih.gov/34530771/.
787. Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or
circumstantial: https://pubmed.ncbi.nlm.nih.gov/34245294/.
788. Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus

disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34599716/.
789. Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual

preponderance of eosinophils: https://pubmed.ncbi.nlm.nih.gov/34115904/.
790. Henoch-Schönlein purpura occurring after vaccination with COVID-

791. Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case
792. Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2

793. Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with
BNT162b2 COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34851795/.
794. A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination
with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34849386/
795. Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-

796. Relapse of microscopic polyangiitis after COVID-19 vaccination: case

797. Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2

798. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on
cyclosporine treatment – A report of 3 cases: https://pubmed.ncbi.nlm.nih.gov/34510694/
799. Leukocytoclastic vasculitis after coronavirus disease vaccination

2019: https://pubmed.ncbi.nlm.nih.gov/34713472/803
800. Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-

801. Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen
802. Case of immunoglobulin A vasculitis after vaccination against coronavirus disease

803. Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA

booster vaccination: case
report: https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/
804. COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression

on FDG PET / CT: https://pubmed.ncbi.nlm.nih.gov/33591026/
805. Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology

patients: https://pubmed.ncbi.nlm.nih.gov/33625300/
806. Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine

Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study
interpretation: https://pubmed.ncbi.nlm.nih.gov/33774684/
807. Lymphadenopathy after COVID-19 vaccination: review of imaging

808. Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG

PET/CT after 2-dose COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34735411/
809. Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing

features in adenovirus-vectored vaccine: https://pubmed.ncbi.nlm.nih.gov/34115709/.
810. COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in
Israel: analysis of 163 cases: https://pubmed.ncbi.nlm.nih.gov/34257025/.
811. COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case

series with literature review: https://pubmed.ncbi.nlm.nih.gov/34836672/.
812. Coronavirus disease vaccine 2019 mimics lymph node metastases in patients
undergoing skin cancer follow-up: a single-center
813. COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy

cytologic findings: https://pubmed.ncbi.nlm.nih.gov/34432391/
814. Regional lymphadenopathy after COVID-19 vaccination: review of the literature and
considerations for patient management in breast cancer
care: https://pubmed.ncbi.nlm.nih.gov/34731748/
815. Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening

mammography: https://pubmed.ncbi.nlm.nih.gov/34906409/
816. Adverse events of COVID injection that may occur in children.Acute-onset

supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against
COVID-19 may be related to the injection technique of the vaccine, Spain, January and February

by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/
818. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline

PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/
819. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA
vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
820. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-
up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/
821. A case of cervical lymphadenopathy following COVID-19

822. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19

vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34096896/
823. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca
COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance
824. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan

for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/
825. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-
826. A systematic review of cases of CNS demyelination following COVID-19

827. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing

presentation in the two-week wait neck lump
clinic: https://pubmed.ncbi.nlm.nih.gov/33685772/
828. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with

current or previous breast cancer and other malignancies: cross-sectional imaging findings on
MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
829. Adenopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625299/.
830. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-
831. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump
clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.
832. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features
and implications for head and neck cancer
services: https://pubmed.ncbi.nlm.nih.gov/34526175/
833. Lymphadenopathy associated with the COVID-19

834. Evolution of lymphadenopathy on PET/MRI after COVID-19

835. Autoimmune hepatitis triggered by SARS-CoV-2

836. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and
literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/.
837. Massive cervical lymphadenopathy following vaccination with COVID-

838. ANCA glomerulonephritis following Modern COVID-19

839. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19

840. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19
841. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening
breast MRI allowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/
842. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic
dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.
843. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19
844. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the

USA: https://pubmed.ncbi.nlm.nih.gov/34655312/.
845. Gastroparesis after Pfizer-BioNTech COVID-19

846. Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA

vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain,
January and February 2021: https://pubmed.ncbi.nlm.nih.gov/33706861/

by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/
848. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline

PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/
849. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA
vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
850. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-
up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/
851. A case of cervical lymphadenopathy following COVID-19

852. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19

vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34096896/
853. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca
COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance
854. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan

for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/
855. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-

856. A systematic review of cases of CNS demyelination following COVID-19

857. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing
presentation in the two-week wait neck lump
clinic: https://pubmed.ncbi.nlm.nih.gov/33685772/
858. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with

current or previous breast cancer and other malignancies: cross-sectional imaging findings on
MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
859. Adenopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625299/.
860. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-
861. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump
clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.
862. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features
and implications for head and neck cancer
services: https://pubmed.ncbi.nlm.nih.gov/34526175/
863. Lymphadenopathy associated with the COVID-19

864. Evolution of lymphadenopathy on PET/MRI after COVID-19

865. Autoimmune hepatitis triggered by SARS-CoV-2

866. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and
literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/.
867. Massive cervical lymphadenopathy following vaccination with COVID-

868. ANCA glomerulonephritis following Modern COVID-19

869. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19

870. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19
871. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening

breast MRI allowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/
872. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic
dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.
873. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19
874. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the

USA: https://pubmed.ncbi.nlm.nih.gov/34655312/.
875. Gastroparesis after Pfizer-BioNTech COVID-19

876. Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S.
(2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with
BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121.
doi:10.1016/j.ijcard.2021.08.018. https://www.ncbi.nlm.nih.gov/pubmed/34416319
877. Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar
Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-
3793. doi:10.1016/j.vaccine.2021.05.087. https://www.ncbi.nlm.nih.gov/pubmed/34092429
878. Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following
COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145.
doi:10.1016/j.radcr.2021.05.033. https://www.ncbi.nlm.nih.gov/pubmed/34025885
879. Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021).
Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM.
doi:10.1093/qjmed/hcab252. https://www.ncbi.nlm.nih.gov/pubmed/34586408
880. Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis
in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132.
doi:10.1016/j.jemermed.2021.09.017. https://www.ncbi.nlm.nih.gov/pubmed/34756746
881. Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D.
(2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med,
385(12), 1078-1090.
doi:10.1056/NEJMoa2110475. https://www.ncbi.nlm.nih.gov/pubmed/34432976
882. Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and
cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-
565. doi:10.4330/wjc.v13.i10.556. https://www.ncbi.nlm.nih.gov/pubmed/34754400
883. Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines.
Circulation, 144(6), 471-484.
doi:10.1161/CIRCULATIONAHA.121.056135. https://www.ncbi.nlm.nih.gov/pubmed/34281357
884. Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021).
Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of
Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11).
doi:10.3390/vaccines9111353. https://www.ncbi.nlm.nih.gov/pubmed/34835284
885. Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning
the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J
Cardiovasc Med (Hagerstown), 23(2), 71-74.
doi:10.2459/JCM.0000000000001232. https://www.ncbi.nlm.nih.gov/pubmed/34366403
886. Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo,
P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis.
Pediatr Rep, 13(3), 530-533.
doi:10.3390/pediatric13030061. https://www.ncbi.nlm.nih.gov/pubmed/34564344
887. Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022).
Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech
COVID-19 vaccine. Acta Paediatr, 111(1), 125-127.
doi:10.1111/apa.16141. https://www.ncbi.nlm.nih.gov/pubmed/34617315
888. Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A.
(2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an
accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res
Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-
w. https://www.ncbi.nlm.nih.gov/pubmed/34333695
889. Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and

Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis.
Medicina (Kaunas), 57(11).
doi:10.3390/medicina57111163. https://www.ncbi.nlm.nih.gov/pubmed/34833382
890. Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac
MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J
Roentgenol. doi:10.2214/AJR.21.26853. https://www.ncbi.nlm.nih.gov/pubmed/34704459
891. Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021).
Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case
Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286.
doi:10.3346/jkms.2021.36.e286. https://www.ncbi.nlm.nih.gov/pubmed/34664804
892. Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P.
(2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a
Global Level. Clin Pharmacol Ther.
doi:10.1002/cpt.2499. https://www.ncbi.nlm.nih.gov/pubmed/34860360
893. Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P.
(2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following
Comirnaty Vaccination. Clin Infect Dis.
doi:10.1093/cid/ciab989. https://www.ncbi.nlm.nih.gov/pubmed/34849657
894. Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent
myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr.
doi:10.1016/j.jpeds.2021.12.026. https://www.ncbi.nlm.nih.gov/pubmed/34933012
895. Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno,
R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis,
112, 243-246. doi:10.1016/j.ijid.2021.09.026. https://www.ncbi.nlm.nih.gov/pubmed/34547487
896. Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D.
(2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in
Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21.
897. Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and
Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel),
8(7). doi:10.3390/children8070607. https://www.ncbi.nlm.nih.gov/pubmed/34356586
898. Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following
COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse
Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230.
doi:10.1177/21501327211029230. https://www.ncbi.nlm.nih.gov/pubmed/34219532
899. Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma,
G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With
mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863.
doi:10.1016/j.jcmg.2021.06.003. https://www.ncbi.nlm.nih.gov/pubmed/34246585
900. Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety
and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis
on treatment with TNF-inhibitors. Arthritis Rheumatol.
doi:10.1002/art.41977. https://www.ncbi.nlm.nih.gov/pubmed/34492161
901. Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021).
Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis
on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-
221607. https://www.ncbi.nlm.nih.gov/pubmed/34844930
902. Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., &
Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19
vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859.
doi:10.1007/s00392-021-01936-6. https://www.ncbi.nlm.nih.gov/pubmed/34487236
903. El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., .
. . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded
Phase. N Engl J Med, 385(19), 1774-1785.
904. Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute
myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11),
891-893. doi:10.1714/3689.36746. https://www.ncbi.nlm.nih.gov/pubmed/34709227
905. Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-
Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A
systematic review of case reports and case series. Rev Med Virol, e2318.
doi:10.1002/rmv.2318. https://www.ncbi.nlm.nih.gov/pubmed/34921468
906. Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino,
C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong
specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-
y. https://www.ncbi.nlm.nih.gov/pubmed/34824230
907. Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring
to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020).
Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical
research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online
publication. https://doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352.
doi:10.1007/s00392-021-01896-x. https://www.ncbi.nlm.nih.gov/pubmed/34170372
908. Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F.
(2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-
19 Vaccines. Eur Heart J Qual Care Clin Outcomes.
doi:10.1093/ehjqcco/qcab090. https://www.ncbi.nlm.nih.gov/pubmed/34849667
909. Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T.
M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and
Pre-Immune Humans. Front Immunol, 12, 728021.
doi:10.3389/fimmu.2021.728021. https://www.ncbi.nlm.nih.gov/pubmed/34646267
910. Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O.
(2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients
with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre
study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-
911. Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical
Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am,
68(5), 961-976.
doi:10.1016/j.pcl.2021.05.004. https://www.ncbi.nlm.nih.gov/pubmed/34538306
912. Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S.
E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine
Recipients: Update from the Advisory Committee on Immunization Practices – United States,
June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982.
doi:10.15585/mmwr.mm7027e2. https://www.ncbi.nlm.nih.gov/pubmed/34237049
913. Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021).
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors:
Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System
and VigiBase. Vaccines (Basel), 9(1).
doi:10.3390/vaccines9010019. https://www.ncbi.nlm.nih.gov/pubmed/33406694
914. Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late
Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890.
doi:10.7759/cureus.17890. https://www.ncbi.nlm.nih.gov/pubmed/34660088
915. Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090.
doi:10.1136/bmj.n3090. https://www.ncbi.nlm.nih.gov/pubmed/34916217
916. Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D.
B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation
and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International
Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567.
doi:10.1016/j.jaip.2021.06.006. https://www.ncbi.nlm.nih.gov/pubmed/34153517
917. Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C.
(2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination
should not discourage vaccination. Swiss Med Wkly, 151, w30087.
doi:10.4414/smw.2021.w30087. https://www.ncbi.nlm.nih.gov/pubmed/34668687
918. Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D.
(2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in
a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-
021-02183-3. https://www.ncbi.nlm.nih.gov/pubmed/34348657
919. Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K.
(2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14,
2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058.
920. Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., &
Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-
CoV-2 Vaccine. J Blood Med, 12, 221-224.
doi:10.2147/JBM.S307047. https://www.ncbi.nlm.nih.gov/pubmed/33854395
921. Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C.
A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and
SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931.
doi:10.1136/bmj.n1931. https://www.ncbi.nlm.nih.gov/pubmed/34446426
922. Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021).
A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J.
doi:10.11622/smedj.2021210. https://www.ncbi.nlm.nih.gov/pubmed/34808708
923. Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021).
Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-
BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214.
924. In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021).
Med Lett Drugs Ther, 63(1629), e9. Retrieved
from https://www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubmed/
3454412
925. Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and
unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM.
926. Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to

confirm an acute inflammatory process. QJM.
927. Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19
Vaccination. Radiology, 301(1), E378-E379.
doi:10.1148/radiol.2021211766. https://www.ncbi.nlm.nih.gov/pubmed/34342500
928. Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., .
. . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19
mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract,
2021(3), e202118.
doi:10.21542/gcsp.2021.18. https://www.ncbi.nlm.nih.gov/pubmed/34805376
929. Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B.
(2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and
Nine Different Variants of SARS-CoV-2. Viruses, 13(11).
doi:10.3390/v13112177. https://www.ncbi.nlm.nih.gov/pubmed/34834983
930. Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-
Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics,
148(5). doi:10.1542/peds.2021-053427. https://www.ncbi.nlm.nih.gov/pubmed/34389692
931. Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . .
Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA
Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939.
doi:10.1093/jpids/piab061. https://www.ncbi.nlm.nih.gov/pubmed/34270752
932. Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With
Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19).
Circ J. doi:10.1253/circj.CJ-21-0818. https://www.ncbi.nlm.nih.gov/pubmed/34744118
933. Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A.
(2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872.
doi:10.1016/j.ijcha.2021.100872. https://www.ncbi.nlm.nih.gov/pubmed/34568540
934. Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis
Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590.
935. Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . .
Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA
Cardiol, 6(10), 1196-1201.
doi:10.1001/jamacardio.2021.2828. https://www.ncbi.nlm.nih.gov/pubmed/34185046
936. Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute
Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229.
937. King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J.
W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart
J Plus, 8, 100042.
doi:10.1016/j.ahjo.2021.100042. https://www.ncbi.nlm.nih.gov/pubmed/34396358
938. Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub,
E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA, 326(14),
1390-1399. doi:10.1001/jama.2021.15072. https://www.ncbi.nlm.nih.gov/pubmed/34477808
939. Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . .
Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper
from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17.
940. Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm,
M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine
in Great Britain and USA: Position statement of the German Allergy Societies: Medical
Association of German Allergologists (AeDA), German Society for Allergology and Clinical
Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA).
Allergo J Int, 30(2), 51-55. doi:10.1007/s40629-020-00160-
941. Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J.
Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey
Study. J Pediatr.
942. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A.
A., & Tsatsakis, A. (2021a). Erratum to “Why are we vaccinating children against COVID-19?”
[Toxicol. Rep. 8C (2021) 1665-1684 / 1193]. Toxicol Rep, 8, 1981.
doi:10.1016/j.toxrep.2021.10.003. https://www.ncbi.nlm.nih.gov/pubmed/34642628
943. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A.
A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? Toxicol Rep, 8,
1665-1684.
doi:10.1016/j.toxrep.2021.08.010. https://www.ncbi.nlm.nih.gov/pubmed/34540594
944. Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . .
Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine
candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr,
133(17-18), 931-941. doi:10.1007/s00508-021-01922-
y. https://www.ncbi.nlm.nih.gov/pubmed/34378087
945. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021).
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-
mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-
946. Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P.
(2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327.
doi:10.12809/hkmj215120. https://www.ncbi.nlm.nih.gov/pubmed/34393110
947. Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor:
Myocarditis should be considered in those with a troponin rise and unobstructed coronary
arteries following PfizerBioNTech COVID-19 vaccination”. QJM.
948. Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . .
Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination.
Am J Hematol, 96(5), 534-537.
doi:10.1002/ajh.26132. https://www.ncbi.nlm.nih.gov/pubmed/33606296
949. Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . .
Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42),
6195-6200.
doi:10.1016/j.vaccine.2021.09.004. https://www.ncbi.nlm.nih.gov/pubmed/34535317
950. Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and
immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese
adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med, 27(6), 1062-
1070. doi:10.1038/s41591-021-01330-9. https://www.ncbi.nlm.nih.gov/pubmed/33888900
951. Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis
following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J Pers Med, 11(11).
doi:10.3390/jpm11111106. https://www.ncbi.nlm.nih.gov/pubmed/34834458
952. Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Case
Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus
Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. Front
Cardiovasc Med, 8, 758996.
doi:10.3389/fcvm.2021.758996. https://www.ncbi.nlm.nih.gov/pubmed/34778411
953. Long, S. S. (2021). Important Insights into Myopericarditis after the Pfizer mRNA COVID-
19 Vaccination in Adolescents. J Pediatr, 238, 5.
954. Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M.
(2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations
for Care Providers. Can J Cardiol, 37(10), 1629-1634.
doi:10.1016/j.cjca.2021.08.001. https://www.ncbi.nlm.nih.gov/pubmed/34375696
955. Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O., . . .
Eberhardt, C. S. (2021). Robust T cell responses in anti-CD20 treated patients following COVID-
19 vaccination: a prospective cohort study. Clin Infect Dis.
956. Mangat, C., & Milosavljevic, N. (2021). BNT162b2 Vaccination during Pregnancy Protects
Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6
Months of Age. Case Rep Pediatr, 2021, 6901131.
doi:10.1155/2021/6901131. https://www.ncbi.nlm.nih.gov/pubmed/34676123
957. Mark, C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . . Alexander, S.
(2021). Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in
youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-
asparaginase. Pediatr Blood Cancer, 68(11), e29295.
doi:10.1002/pbc.29295. https://www.ncbi.nlm.nih.gov/pubmed/34398511
958. Martins-Filho, P. R., Quintans-Junior, L. J., de Souza Araujo, A. A., Sposato, K. B., Souza
Tavares, C. S., Gurgel, R. Q., . . . Santos, V. S. (2021). Socio-economic inequalities and COVID-19
incidence and mortality in Brazilian children: a nationwide register-based study. Public Health,
190, 4-6. doi:10.1016/j.puhe.2020.11.005. https://www.ncbi.nlm.nih.gov/pubmed/33316478
959. McLean, K., & Johnson, T. J. (2021). Myopericarditis in a previously healthy adolescent
male following COVID-19 vaccination: A case report. Acad Emerg Med, 28(8), 918-921.
doi:10.1111/acem.14322. https://www.ncbi.nlm.nih.gov/pubmed/34133825
960. Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S.
(2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med,
385(23), 2140-2149.
961. Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute
Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-
19) Vaccine in a Male Adolescent. J Pediatr, 238, 321-323.
962. Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., . . . Patalon, T.
(2021). Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun,
12(1), 6379. doi:10.1038/s41467-021-26672-
963. Moffitt, K., Cheung, E., Yeung, T., Stamoulis, C., & Malley, R. (2021). Analysis of
Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and Comparison to
Murine Infections. Infect Immun, 89(4). doi:10.1128/IAI.00715-
964. Mohamed, L., Madsen, A. M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M. G.,
Benn, C. S., & Kofoed, P. E. (2021). Reactivation of BCG vaccination scars after vaccination with
mRNA-Covid-vaccines: two case reports. BMC Infect Dis, 21(1), 1264. doi:10.1186/s12879-021-
06949-0. https://www.ncbi.nlm.nih.gov/pubmed/34930152
965. Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . .
Cooper, L. T., Jr. (2021). Myocarditis Following Immunization With mRNA COVID-19 Vaccines in
Members of the US Military. JAMA Cardiol, 6(10), 1202-1206.
doi:10.1001/jamacardio.2021.2833. https://www.ncbi.nlm.nih.gov/pubmed/34185045
966. Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021).
Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern
Med. doi:10.2169/internalmedicine.8731-21. https://www.ncbi.nlm.nih.gov/pubmed/34840235
967. Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . .
Kaneko, Y. (2021). Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. J
Cardiol Cases.
doi:10.1016/j.jccase.2021.11.006. https://www.ncbi.nlm.nih.gov/pubmed/34876937
968. Ntouros, P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P., Tektonidou,
M. G., . . . Sfikakis, P. P. (2021). Effective DNA damage response after acute but not chronic
immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. Clin Immunol,
229, 108765.
doi:10.1016/j.clim.2021.108765. https://www.ncbi.nlm.nih.gov/pubmed/34089859
969. Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B., . . .
Stensballe, L. G. (2022). Population-based Incidence of Myopericarditis After COVID-19
Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28.
doi:10.1097/INF.0000000000003389. https://www.ncbi.nlm.nih.gov/pubmed/34889875
970. Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., . . .
Hofmann, M. (2021). Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA
vaccine. Nature, 597(7875), 268-273. doi:10.1038/s41586-021-03841-
971. Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J. (2021).
Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA
COVID-19 Vaccine in Korean Children: a Multicenter Study. J Korean Med Sci, 36(32), e232.
972. Park, J., Brekke, D. R., & Bratincsak, A. (2021). Self-limited myocarditis presenting with
chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA
vaccine. Cardiol Young, 1-4.
doi:10.1017/S1047951121002547. https://www.ncbi.nlm.nih.gov/pubmed/34180390
973. Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). Cardiovascular
magnetic resonance findings in young adult patients with acute myocarditis following mRNA
COVID-19 vaccination: a case series. J Cardiovasc Magn Reson, 23(1), 101. doi:10.1186/s12968-
021-00795-4. https://www.ncbi.nlm.nih.gov/pubmed/34496880
974. Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . .
Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated
with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. doi:10.1038/s41591-021-01630-
975. Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., &
Mariani, A. (2021). Acute myocarditis following Comirnaty vaccination in a healthy man with
previous SARS-CoV-2 infection. Radiol Case Rep, 16(11), 3321-3325.
doi:10.1016/j.radcr.2021.07.082. https://www.ncbi.nlm.nih.gov/pubmed/34367386
976. Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . . Swift,
M. D. (2021). Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate
Determination. Clin Infect Dis.
977. Perrotta, A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G., . . .
Peruzzi, M. (2021). A snapshot global survey on side effects of COVID-19 vaccines among
healthcare professionals and armed forces with a focus on headache. Panminerva Med, 63(3),
324-331. doi:10.23736/S0031-0808.21.04435-
978. Pinana, J. L., Lopez-Corral, L., Martino, R., Montoro, J., Vazquez, L., Perez, A., . . . Cell
Therapy, G. (2022). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in
hematopoietic stem cell transplant recipients: Prospective survey from the Spanish
Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol, 97(1), 30-42.
doi:10.1002/ajh.26385. https://www.ncbi.nlm.nih.gov/pubmed/34695229
979. Revon-Riviere, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., . . . Andre, N.
(2021). The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A
monocentric experience. Eur J Cancer, 154, 30-34.
doi:10.1016/j.ejca.2021.06.002. https://www.ncbi.nlm.nih.gov/pubmed/34233234
980. Sanchez Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A., & Hanneman, K.
(2021). Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art
Review and Update on Myocarditis Associated with COVID-19 Vaccination. Radiol Cardiothorac
Imaging, 3(6), e210252.
doi:10.1148/ryct.210252. https://www.ncbi.nlm.nih.gov/pubmed/34934954
981. Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa, S., &
Portman, M. A. (2021). Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus
Disease Vaccine in Adolescents. J Pediatr, 238, 317-320.
982. Schneider, J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C., . . .
Schmeling, A. (2021). Postmortem investigation of fatalities following vaccination with COVID-19
vaccines. Int J Legal Med, 135(6), 2335-2345. doi:10.1007/s00414-021-02706-
983. Schramm, R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken, U., . . .
Gummert, J. (2021). Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA
vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res Cardiol, 110(8), 1142-1149.
984. Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C. (2021).
Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A
Systematic Review. J Clin Med, 10(24).
doi:10.3390/jcm10245876. https://www.ncbi.nlm.nih.gov/pubmed/34945172
985. Sharif, N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021). Efficacy, Immunogenicity
and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol, 12,
714170. doi:10.3389/fimmu.2021.714170. https://www.ncbi.nlm.nih.gov/pubmed/34707602
986. Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., . . . Shimabukuro, T. T.
(2021). Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine – United
States, March-April 2021. MMWR Morb Mortal Wkly Rep, 70(18), 680-684.
987. Shazley, O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented With
Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson &
Johnson Vaccination: A Case-Study. Cureus, 13(7), e16383.
988. Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan, A.
(2021). Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. Eur
Heart J Cardiovasc Imaging.
doi:10.1093/ehjci/jeab230. https://www.ncbi.nlm.nih.gov/pubmed/34739045
989. Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021).
Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older.
JAMA Intern Med, 181(12), 1668-1670.
doi:10.1001/jamainternmed.2021.5511. https://www.ncbi.nlm.nih.gov/pubmed/34605853
990. Singer, M. E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis from COVID-19
Infection in People Under Age 20: A Population-Based Analysis. medRxiv.
doi:10.1101/2021.07.23.21260998. https://www.ncbi.nlm.nih.gov/pubmed/34341797
991. Smith, C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . . Fraser, L. K. (2021).
Deaths in children and young people in England after SARS-CoV-2 infection during the first
pandemic year. Nat Med. doi:10.1038/s41591-021-01578-
992. Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I.,
. . . Bilavsky, E. (2021). Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA
COVID-19 Vaccine. Pediatr Infect Dis J, 40(10), e360-e363.
doi:10.1097/INF.0000000000003235. https://www.ncbi.nlm.nih.gov/pubmed/34077949
993. Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Munoz, F. M., &
Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart
transplantation: A first report. J Heart Lung Transplant.
doi:10.1016/j.healun.2021.11.001. https://www.ncbi.nlm.nih.gov/pubmed/34911654
994. Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L., & Reeder, S.
B. (2021). Myocarditis Associated with mRNA COVID-19 Vaccination. Radiology, 301(2), E409-
E411. doi:10.1148/radiol.2021211430. https://www.ncbi.nlm.nih.gov/pubmed/34282971
995. Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association between
the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review.
Cardiovasc Revasc Med.
doi:10.1016/j.carrev.2021.08.012. https://www.ncbi.nlm.nih.gov/pubmed/34420869
996. Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute
myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur Heart J Case Rep,
5(8), ytab319. doi:10.1093/ehjcr/ytab319. https://www.ncbi.nlm.nih.gov/pubmed/34514306
997. Takeda, M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021).
Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination. Circ J.
doi:10.1253/circj.CJ-21-0935. https://www.ncbi.nlm.nih.gov/pubmed/34955479
998. Team, C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis After
Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14-23,
2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51.
999. Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., . . .
Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273
Vaccines. N Engl J Med, 385(4), 320-329.
1000. Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021).
Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol, 15,
11795468211056634.
doi:10.1177/11795468211056634. https://www.ncbi.nlm.nih.gov/pubmed/34866957
1001. Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., . . .
Newburger, J. W. (2021). Clinically Suspected Myocarditis Temporally Related to COVID-19
Vaccination in Adolescents and Young Adults. Circulation.
doi:10.1161/CIRCULATIONAHA.121.056583. https://www.ncbi.nlm.nih.gov/pubmed/34865500
1002. Tutor, A., Unis, G., Ruiz, B., Bolaji, O. A., & Bob-Manuel, T. (2021). Spectrum of
Suspected Cardiomyopathy Due to COVID-19: A Case Series. Curr Probl Cardiol, 46(10), 100926.
doi:10.1016/j.cpcardiol.2021.100926. https://www.ncbi.nlm.nih.gov/pubmed/34311983
1003. Umei, T. C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021).
Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC
Open. doi:10.1016/j.cjco.2021.12.002. https://www.ncbi.nlm.nih.gov/pubmed/34904134
1004. Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V. A., & Han, Y.
(2021). Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19
Vaccines. Cureus, 13(6), e15576.
1005. Visclosky, T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis Following
mRNA COVID-19 Vaccine. Pediatr Emerg Care, 37(11), 583-584.
doi:10.1097/PEC.0000000000002557. https://www.ncbi.nlm.nih.gov/pubmed/34731877
1006. Warren, C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., . . . Nadeau,
K. C. (2021). Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines
With Confirmatory Testing in a US Regional Health System. JAMA Netw Open, 4(9), e2125524.
doi:10.1001/jamanetworkopen.2021.25524. https://www.ncbi.nlm.nih.gov/pubmed/34533570
1007. Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis after BNT162b2
vaccination in a healthy male. Am J Emerg Med, 50, 815 e811-815 e812.
doi:10.1016/j.ajem.2021.06.051. https://www.ncbi.nlm.nih.gov/pubmed/34229940
1008. Weitzman, E. R., Sherman, A. C., & Levy, O. (2021). SARS-CoV-2 mRNA Vaccine Attitudes
as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning
Immunization System. Front Public Health, 9, 695807.
doi:10.3389/fpubh.2021.695807. https://www.ncbi.nlm.nih.gov/pubmed/34336774
1009. Welsh, K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021). Thrombocytopenia
including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the
Vaccine Adverse Event Reporting System (VAERS). Vaccine, 39(25), 3329-3332.
doi:10.1016/j.vaccine.2021.04.054. https://www.ncbi.nlm.nih.gov/pubmed/34006408
1010. Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R.
(2021). Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J
Med, 385(23), 2132-2139.
1011. Zimmermann, P., & Curtis, N. (2020). Why is COVID-19 less severe in children? A review
of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2
infections. Arch Dis Child. doi:10.1136/archdischild-2020-
SOURCE LINK: https://www.saveusnow.org.uk/covid-vaccine-scientific-proof-lethal/

Covid Vaccine Scientific Proof

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Covid Vaccine Scientific Proof

Uploaded by

Copyright:

Available Formats

Covid Vaccine Scientific Proof Lethal

• Post published:5 January 2022

COVID-19 Vaccines: Scientific Proof of Lethality

Post published: 5 January 2022 at https://www.saveusnow.org.uk/covid-vaccine-scientific-proof-lethal

2. Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular

3. Fatal cerebral hemorrhage after COVID-19

4. Myocarditis after mRNA vaccination against SARS-CoV-2, a case

6. Acute thrombosis of the coronary tree after vaccination against COVID-

8. Portal vein thrombosis associated with ChAdOx1 nCov-19

9. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in

11. Thrombosis with thrombocytopenia syndrome associated with COVID-19

12. Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important

14. COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause

16. Roots of autoimmunity of thrombotic events after COVID-19

18. Thrombotic immune thrombocytopenia induced by SARS-CoV-2

20. Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-

22. Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-

23. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-

24. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA

25. Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19

27. Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and

30. Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2

35. Myocarditis, pericarditis and cardiomyopathy after COVID-19

36. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT)

37. Prothrombotic immune thrombocytopenia after COVID-19

38. Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success

40. Thrombosis after COVID-19 vaccination: possible link to ACE

49. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2

50. Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2

51. Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19

53. Cerebral venous thrombosis associated with the covid-19 vaccine in

55. The importance of recognizing cerebral venous thrombosis following anti-COVID-19

56. Thrombosis with thrombocytopenia after messenger RNA vaccine -

59. Exacerbation of immune thrombocytopenia after COVID-19

61. PF4 immunoassays in vaccine-induced thrombotic

62. Antibody epitopes in vaccine-induced immune immune thrombotic

63. Myocarditis with COVID-19 mRNA

64. Myocarditis and pericarditis after COVID-19

65. Myocarditis temporally associated with COVID-19

66. COVID-19 Vaccination Associated with Myocarditis in

67. Acute myocarditis after administration of BNT162b2 vaccine against COVID-

69. COVID-19 vaccine-induced myocarditis: a case report with review of the

74. Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral

75. Myocarditis following vaccination with BNT162b2 in a healthy

77. Myopericarditis after Pfizer mRNA COVID-19 vaccination in

78. Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA

79. Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273

81. Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of

82. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old

85. Takotsubo cardiomyopathy after vaccination with mRNA COVID-

86. COVID-19 mRNA vaccination and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34268277/

87. COVID-19 vaccine and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34399967/

89. COVID-19 vaccines and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34246566/

90. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19

91. Myocarditis, pericarditis, and cardiomyopathy after COVID-19

92. Myocarditis with covid-19 mRNA

93. Association of myocarditis with COVID-19 mRNA vaccine in

96. Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19

97. Myocarditis following immunization with Covid-19

98. Patients with acute myocarditis after vaccination withCOVID-19

99. Myocarditis associated with vaccination with COVID-19

100. Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19

103. Cardiac imaging of acute myocarditis after vaccination with COVID-19

105. Myocarditis / pericarditis associated with COVID-19